1
|
Singh N, MacNicol E, DiPasquale O, Randall K, Lythgoe D, Mazibuko N, Simmons C, Selvaggi P, Stephenson S, Turkheimer FE, Cash D, Zelaya F, Colasanti A. The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats. J Cereb Blood Flow Metab 2023; 43:95-105. [PMID: 36803299 PMCID: PMC10638993 DOI: 10.1177/0271678x231157958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 11/09/2022] [Accepted: 12/26/2022] [Indexed: 02/23/2023]
Abstract
Methylene Blue (MB) is a brain-penetrating drug with putative neuroprotective, antioxidant and metabolic enhancing effects. In vitro studies suggest that MB enhances mitochondrial complexes activity. However, no study has directly assessed the metabolic effects of MB in the human brain. We used in vivo neuroimaging to measure the effect of MB on cerebral blood flow (CBF) and brain metabolism in humans and in rats. Two doses of MB (0.5 and 1 mg/kg in humans; 2 and 4 mg/kg in rats; iv) induced reductions in global cerebral blood flow (CBF) in humans (F(1.74, 12.17)5.82, p = 0.02) and rats (F(1,5)26.04, p = 0.0038). Human cerebral metabolic rate of oxygen (CMRO2) was also significantly reduced (F(1.26, 8.84)8.01, p = 0.016), as was the rat cerebral metabolic rate of glucose (CMRglu) (t = 2.6(16) p = 0.018). This was contrary to our hypothesis that MB will increase CBF and energy metrics. Nevertheless, our results were reproducible across species and dose dependent. One possible explanation is that the concentrations used, although clinically relevant, reflect MB's hormetic effects, i.e., higher concentrations produce inhibitory rather than augmentation effects on metabolism. Additionally, here we used healthy volunteers and healthy rats with normal cerebral metabolism where MB's ability to enhance cerebral metabolism might be limited.
Collapse
Affiliation(s)
- Nisha Singh
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Eilidh MacNicol
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Ottavia DiPasquale
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Karen Randall
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - David Lythgoe
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Ndabezinhle Mazibuko
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Pierluigi Selvaggi
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Stephanie Stephenson
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Federico E Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Fernando Zelaya
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Alessandro Colasanti
- Department of Clinical Neuroscience and Neuroimaging, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
- Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| |
Collapse
|
2
|
Serrano ME, Kim E, Siow B, Ma D, Rojo L, Simmons C, Hayward D, Gibbins D, Singh N, Strydom A, Fisher EM, Tybulewicz VL, Cash D. Investigating brain alterations in the Dp1Tyb mouse model of Down syndrome. Neurobiol Dis 2023; 188:106336. [PMID: 38317803 PMCID: PMC7615598 DOI: 10.1016/j.nbd.2023.106336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2024] Open
Abstract
Down syndrome (DS) is one of the most common birth defects and the most prevalent genetic form of intellectual disability. DS arises from trisomy of chromosome 21, but its molecular and pathological consequences are not fully understood. In this study, we compared Dp1Tyb mice, a DS model, against their wild-type (WT) littermates of both sexes to investigate the impact of DS-related genetic abnormalities on the brain phenotype. We performed in vivo whole brain magnetic resonance imaging (MRI) and hippocampal 1H magnetic resonance spectroscopy (MRS) on the animals at 3 months of age. Subsequently, ex vivo MRI scans and histological analyses were conducted post-mortem. Our findings unveiled the following neuroanatomical and biochemical alterations in the Dp1Tyb brains: a smaller surface area and a rounder shape compared to WT brains, with DS males also presenting smaller global brain volume compared with the counterpart WT. Regional volumetric analysis revealed significant changes in 26 out of 72 examined brain regions, including the medial prefrontal cortex and dorsal hippocampus. These alterations were consistently observed in both in vivo and ex vivo imaging data. Additionally, high-resolution ex vivo imaging enabled us to investigate cerebellar layers and hippocampal sub-regions, revealing selective areas of decrease and remodelling in these structures. An analysis of hippocampal metabolites revealed an elevation in glutamine and the glutamine/glutamate ratio in the Dp1Tyb mice compared to controls, suggesting a possible imbalance in the excitation/inhibition ratio. This was accompanied by the decreased levels of taurine. Histological analysis revealed fewer neurons in the hippocampal CA3 and DG layers, along with an increase in astrocytes and microglia. These findings recapitulate multiple neuroanatomical and biochemical features associated with DS, enriching our understanding of the potential connection between chromosome 21 trisomy and the resultant phenotype.
Collapse
Affiliation(s)
- Maria Elisa Serrano
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Bernard Siow
- The Francis Crick Institute, London, United Kingdom
| | - Da Ma
- Department of Internal Medicine Section of Gerontology and Geriatric Science, Wake Forest University School of Medicine, Winston-Salem, NC, United States
| | - Loreto Rojo
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | | | | | - Nisha Singh
- Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - Andre Strydom
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
| | - Elizabeth M.C. Fisher
- UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK
| | | | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| |
Collapse
|
3
|
Kim E, Carreira Figueiredo I, Simmons C, Randall K, Rojo Gonzalez L, Wood T, Ranieri B, Sureda-Gibert P, Howes O, Pariante C, Nima Consortium, Pasternak O, Dell'Acqua F, Turkheimer F, Cash D. Mapping acute neuroinflammation in vivo with diffusion-MRI in rats given a systemic lipopolysaccharide challenge. Brain Behav Immun 2023; 113:289-301. [PMID: 37482203 DOI: 10.1016/j.bbi.2023.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 06/19/2023] [Accepted: 07/17/2023] [Indexed: 07/25/2023] Open
Abstract
It is becoming increasingly apparent that neuroinflammation plays a critical role in an array of neurological and psychiatric disorders. Recent studies have demonstrated the potential of diffusion MRI (dMRI) to characterize changes in microglial density and morphology associated with neuroinflammation, but these were conducted mostly ex vivo and/or in extreme, non-physiological animal models. Here, we build upon these studies by investigating the utility of well-established dMRI methods to detect neuroinflammation in vivo in a more clinically relevant animal model of sickness behavior. We show that diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI) indicate widespread increases in diffusivity in the brains of rats given a systemic lipopolysaccharide challenge (n = 20) vs. vehicle-treated controls (n = 12). These diffusivity changes correlated with histologically measured changes in microglial morphology, confirming the sensitivity of dMRI to neuroinflammatory processes. This study marks a further step towards establishing a noninvasive indicator of neuroinflammation, which would greatly facilitate early diagnosis and treatment monitoring in various neurological and psychiatric diseases.
Collapse
Affiliation(s)
- Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Ines Carreira Figueiredo
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Karen Randall
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Loreto Rojo Gonzalez
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Tobias Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Brigida Ranieri
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Paula Sureda-Gibert
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Oliver Howes
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Carmine Pariante
- Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Nima Consortium
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), United Kingdom
| | - Ofer Pasternak
- Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| | - Flavio Dell'Acqua
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
| |
Collapse
|
4
|
Monari S, Guillot de Suduiraut I, Grosse J, Zanoletti O, Walker SE, Mesquita M, Wood TC, Cash D, Astori S, Sandi C. Blunted Glucocorticoid Responsiveness to Stress Causes Behavioral and Biological Alterations That Lead to Posttraumatic Stress Disorder Vulnerability. Biol Psychiatry 2023:S0006-3223(23)01590-1. [PMID: 37743003 DOI: 10.1016/j.biopsych.2023.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/24/2023] [Accepted: 09/15/2023] [Indexed: 09/26/2023]
Abstract
BACKGROUND Understanding why only a subset of trauma-exposed individuals develop posttraumatic stress disorder is critical for advancing clinical strategies. A few behavioral (deficits in fear extinction) and biological (blunted glucocorticoid levels, small hippocampal size, and rapid-eye-movement sleep [REMS] disturbances) traits have been identified as potential vulnerability factors. However, whether and to what extent these traits are interrelated and whether one of them could causally engender the others are not known. METHODS In a genetically selected rat model of reduced corticosterone responsiveness to stress, we explored posttraumatic stress disorder-related biobehavioral traits using ex vivo magnetic resonance imaging, cued fear conditioning, and polysomnographic recordings combined with in vivo photometric measurements. RESULTS We showed that genetic selection for blunted glucocorticoid responsiveness led to a correlated multitrait response, including impaired fear extinction (observed in males but not in females), small hippocampal volume, and REMS disturbances, supporting their interrelatedness. Fear extinction deficits and concomitant disruptions in REMS could be normalized through postextinction corticosterone administration, causally implicating glucocorticoid deficiency in two core posttraumatic stress disorder-related risk factors and manifestations. Furthermore, reduced REMS was accompanied by higher norepinephrine levels in the hippocampal dentate gyrus that were also reversed by postextinction corticosterone treatment. CONCLUSIONS Our results indicate a predominant role for glucocorticoid deficiency over the contribution of reduced hippocampal volume in engendering both REMS alterations and associated deficits in fear extinction consolidation, and they causally implicate blunted glucocorticoids in sustaining neurophysiological disturbances that lead to fear extinction deficits.
Collapse
Affiliation(s)
- Silvia Monari
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Isabelle Guillot de Suduiraut
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Synapsy Center for Neuroscience and Mental Health Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Jocelyn Grosse
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Synapsy Center for Neuroscience and Mental Health Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Olivia Zanoletti
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Synapsy Center for Neuroscience and Mental Health Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Sophie E Walker
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Michel Mesquita
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Tobias C Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Simone Astori
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Synapsy Center for Neuroscience and Mental Health Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
| | - Carmen Sandi
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Synapsy Center for Neuroscience and Mental Health Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
| |
Collapse
|
5
|
Raheel K, Deegan G, Di Giulio I, Cash D, Ilic K, Gnoni V, Chaudhuri KR, Drakatos P, Moran R, Rosenzweig I. Sex differences in alpha-synucleinopathies: a systematic review. Front Neurol 2023; 14:1204104. [PMID: 37545736 PMCID: PMC10398394 DOI: 10.3389/fneur.2023.1204104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 06/13/2023] [Indexed: 08/08/2023] Open
Abstract
Background Past research indicates a higher prevalence, incidence, and severe clinical manifestations of alpha-synucleinopathies in men, leading to a suggestion of neuroprotective properties of female sex hormones (especially estrogen). The potential pathomechanisms of any such effect on alpha-synucleinopathies, however, are far from understood. With that aim, we undertook to systematically review, and to critically assess, contemporary evidence on sex and gender differences in alpha-synucleinopathies using a bench-to-bedside approach. Methods In this systematic review, studies investigating sex and gender differences in alpha-synucleinopathies (Rapid Eye Movement (REM) Behavior Disorder (RBD), Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA)) from 2012 to 2022 were identified using electronic database searches of PubMed, Embase and Ovid. Results One hundred sixty-two studies were included; 5 RBD, 6 MSA, 20 DLB and 131 PD studies. Overall, there is conclusive evidence to suggest sex-and gender-specific manifestation in demographics, biomarkers, genetics, clinical features, interventions, and quality of life in alpha-synucleinopathies. Only limited data exists on the effects of distinct sex hormones, with majority of studies concentrating on estrogen and its speculated neuroprotective effects. Conclusion Future studies disentangling the underlying sex-specific mechanisms of alpha-synucleinopathies are urgently needed in order to enable novel sex-specific therapeutics.
Collapse
Affiliation(s)
- Kausar Raheel
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
| | - Gemma Deegan
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- BRAIN, Imaging Centre, CNS, King’s College London, London, United Kingdom
| | - Irene Di Giulio
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- School of Basic and Medical Biosciences, Faculty of Life Science and Medicine, King’s College London, London, United Kingdom
| | - Diana Cash
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- BRAIN, Imaging Centre, CNS, King’s College London, London, United Kingdom
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
| | - Katarina Ilic
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- BRAIN, Imaging Centre, CNS, King’s College London, London, United Kingdom
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
| | - Valentina Gnoni
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro, Lecce, Italy
| | - K. Ray Chaudhuri
- Movement Disorders Unit, King’s College Hospital and Department of Clinical and Basic Neurosciences, Institute of Psychiatry, Psychology and Neuroscience and Parkinson Foundation Centre of Excellence, King’s College London, London, United Kingdom
| | - Panagis Drakatos
- School of Basic and Medical Biosciences, Faculty of Life Science and Medicine, King’s College London, London, United Kingdom
- Sleep Disorders Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Rosalyn Moran
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
| | - Ivana Rosenzweig
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom
- Sleep Disorders Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
6
|
Turkheimer FE, Veronese M, Mondelli V, Cash D, Pariante CM. Sickness behaviour and depression: An updated model of peripheral-central immunity interactions. Brain Behav Immun 2023; 111:202-210. [PMID: 37076054 DOI: 10.1016/j.bbi.2023.03.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 03/15/2023] [Accepted: 03/26/2023] [Indexed: 04/21/2023] Open
Abstract
Current research into mood disorders indicates that circulating immune mediators participating in the pathophysiology of chronic somatic disorders have potent influences on brain function. This paradigm has brought to the fore the use of anti-inflammatory therapies as adjunctive to standard antidepressant therapy to improve treatment efficacy, particularly in subjects that do not respond to standard medication. Such new practice requires biomarkers to tailor these new therapies to those most likely to benefit but also validated mechanisms of action describing the interaction between peripheral immunity and brain function to optimize target intervention. These mechanisms are generally studied in preclinical models that try to recapitulate the human disease, MDD, through peripherally induced sickness behaviour. In this proposal paper, after an appraisal of the data in rodent models and their adherence to the data in clinical cohorts, we put forward a modified model of periphery-brain interactions that goes beyond the currently established view of microglia cells as the drivers of depression. Instead, we suggest that, for most patients with mild levels of peripheral inflammation, brain barriers are the primary actors in the pathophysiology of the disease and in treatment resistance. We then highlight data gaps in this proposal and suggest novel lines of research.
Collapse
Affiliation(s)
- Federico E Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; Department of Information Engineering, University of Padova, Padova, Italy
| | - Valeria Mondelli
- Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Carmine M Pariante
- Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom
| |
Collapse
|
7
|
Kakanos SG, Gadiagellan D, Kim E, Cash D, Moon LDF. ReachingBot: an automated and scalable benchtop device for highly parallel Single Pellet Reach-and-Grasp training and assessment in mice. J Neurosci Methods 2023:109908. [PMID: 37331430 DOI: 10.1016/j.jneumeth.2023.109908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 05/21/2023] [Accepted: 06/15/2023] [Indexed: 06/20/2023]
Abstract
BACKGROUND The single pellet reaching and grasp (SPRG) task is a behavioural assay widely used to study motor learning, control and recovery after nervous system injury in animals. The manual training and assessment of the SPRG is labour intensive and time consuming and has led to the development of multiple devices which automate the SPRG task. NEW METHOD Here, using robotics, computer vision, and machine learning analysis of videos, we describe a device that can be left unattended, presents pellets to mice, and, using two supervised learning algorithms, classifies the outcome of each trial with an accuracy of greater than 94% without the use of graphical processing units (GPUs). Our devices can also be operated using our cross-platform Graphical User Interface (GUI). RESULTS We show that these devices train and assess mice in parallel. 21 out of 30 mice retrieved >40% of pellets successfully following the training period. Following ischaemic stroke; some mice showed large persistent deficits whilst others showed only transient deficits. This highlights the heterogeneity in reaching outcomes following stroke. COMPARISON WITH EXISTING METHOD(S) Current state-of-the-art desktop methods either still require supervision, manual classification of trial outcome, or expensive locally-installed hardware such as graphical processing units (GPUs). CONCLUSIONS ReachingBots successfully automated SPRG training and assessment and revealed the heterogeneity in reaching outcomes following stroke. We conjecture that reach-and-grasp is represented in motor cortex bilaterally but with greater asymmetry in some mice than in others.
Collapse
Affiliation(s)
- Sotiris G Kakanos
- Wolfson Centre for Age Related Diseases, King's College London, University of London, 16-20 Newcomen Street Guy's Campus, London, SE1 1UL, UK; Autoscientific, Bank House, 6 - 8 Church Street, Adlington, Chorley, Lancashire, PR7 4EX
| | - Dhireshan Gadiagellan
- Wolfson Centre for Age Related Diseases, King's College London, University of London, 16-20 Newcomen Street Guy's Campus, London, SE1 1UL, UK
| | - Eugene Kim
- James Black Centre, King's College London, 125 Coldharbour Lane, London, SE5 9NU, UK
| | - Diana Cash
- James Black Centre, King's College London, 125 Coldharbour Lane, London, SE5 9NU, UK
| | - Lawrence D F Moon
- Wolfson Centre for Age Related Diseases, King's College London, University of London, 16-20 Newcomen Street Guy's Campus, London, SE1 1UL, UK.
| |
Collapse
|
8
|
Kiemes A, Serrano Navacerrada ME, Kim E, Randall K, Simmons C, Rojo Gonzalez L, Petrinovic MM, Lythgoe DJ, Rotaru D, Di Censo D, Hirschler L, Barbier EL, Vernon AC, Stone JM, Davies C, Cash D, Modinos G. Erbb4 Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes. Schizophr Bull 2023; 49:569-580. [PMID: 36573631 PMCID: PMC10154722 DOI: 10.1093/schbul/sbac192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND AND HYPOTHESIS Converging lines of evidence suggest that dysfunction of cortical GABAergic inhibitory interneurons is a core feature of psychosis. This dysfunction is thought to underlie neuroimaging abnormalities commonly found in patients with psychosis, particularly in the hippocampus. These include increases in resting cerebral blood flow (CBF) and glutamatergic metabolite levels, and decreases in ligand binding to GABAA α5 receptors and to the synaptic density marker synaptic vesicle glycoprotein 2A (SV2A). However, direct links between inhibitory interneuron dysfunction and these neuroimaging readouts are yet to be established. Conditional deletion of a schizophrenia susceptibility gene, the tyrosine kinase receptor Erbb4, from cortical and hippocampal inhibitory interneurons leads to synaptic defects, and behavioral and cognitive phenotypes relevant to psychosis in mice. STUDY DESIGN Here, we investigated how this inhibitory interneuron disruption affects hippocampal in vivo neuroimaging readouts. Adult Erbb4 conditional mutant mice (Lhx6-Cre;Erbb4F/F, n = 12) and their wild-type littermates (Erbb4F/F, n = 12) were scanned in a 9.4T magnetic resonance scanner to quantify CBF and glutamatergic metabolite levels (glutamine, glutamate, GABA). Subsequently, we assessed GABAA receptors and SV2A density using quantitative autoradiography. RESULTS Erbb4 mutant mice showed significantly elevated ventral hippccampus CBF and glutamine levels, and decreased SV2A density across hippocampus sub-regions compared to wild-type littermates. No significant GABAA receptor density differences were identified. CONCLUSIONS These findings demonstrate that specific disruption of cortical inhibitory interneurons in mice recapitulate some of the key neuroimaging findings in patients with psychosis, and link inhibitory interneuron deficits to non-invasive measures of brain function and neurochemistry that can be used across species.
Collapse
Affiliation(s)
- Amanda Kiemes
- Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Maria Elisa Serrano Navacerrada
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Eugene Kim
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Karen Randall
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Camilla Simmons
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Loreto Rojo Gonzalez
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Marija-Magdalena Petrinovic
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
- Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - David J Lythgoe
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Diana Rotaru
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Davide Di Censo
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Lydiane Hirschler
- C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Emmanuel L Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Anthony C Vernon
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
- Department of Basic and Clinical Neuroscience, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - James M Stone
- Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - Cathy Davies
- Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Diana Cash
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
| | - Gemma Modinos
- Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
- Department of Neuroimaging, School of Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
| |
Collapse
|
9
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. Author Correction: A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023:10.1038/s41593-023-01328-1. [PMID: 37072562 DOI: 10.1038/s41593-023-01328-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Affiliation(s)
- Joanes Grandjean
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands.
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
| | - Gabriel Desrosiers-Gregoire
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada
| | - Cynthia Anckaerts
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Diego Angeles-Valdez
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Fadi Ayad
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - David A Barrière
- UMR INRAE/CNRS 7247 Physiologie des Comportements et de la Reproduction, Physiologie de la reproduction et des comportements, Centre de recherche INRAE de Nouzilly, Tours, France
| | - Ines Blockx
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Aleksandra Bortel
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Margaret Broadwater
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Beatriz M Cardoso
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Marina Célestine
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Jorge E Chavez-Negrete
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Sangcheon Choi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Emma Christiaen
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Perrin Clavijo
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Luis Colon-Perez
- Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Samuel Cramer
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Tolomeo Daniele
- Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Elaine Dempsey
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Yujian Diao
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Laboratory for Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Arno Doelemeyer
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - David Dopfel
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Lenka Dvořáková
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Claudia Falfán-Melgoza
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Francisca F Fernandes
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Caitlin F Fowler
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
| | - Antonio Fuentes-Ibañez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Clément M Garin
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Eveline Gelderman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Carla E M Golden
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Chao C G Guo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Marloes J A G Henckens
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Lauren A Hennessy
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Peter Herman
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Nita Hofwijks
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Corey Horien
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Tudor M Ionescu
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Jolyon Jones
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Johannes Kaesser
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Eugene Kim
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Henriette Lambers
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Alberto Lazari
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Sung-Ho Lee
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amanda Lillywhite
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
| | - Yikang Liu
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Yanyan Y Liu
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Alejandra López-Castro
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Xavier López-Gil
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Zilu Ma
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Eilidh MacNicol
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Dan Madularu
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Center for Translational Neuroimaging, Northeastern University, Boston, MA, USA
| | - Francesca Mandino
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Sabina Marciano
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Matthew J McAuslan
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
| | - Patrick McCunn
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Alison McIntosh
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Xianzong Meng
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Lisa Meyer-Baese
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Stephan Missault
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Federico Moro
- Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Daphne M P Naessens
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Laura J Nava-Gomez
- Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, México
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | - Hiroi Nonaka
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Juan J Ortiz
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jaakko Paasonen
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Lore M Peeters
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Mickaël Pereira
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Pablo D Perez
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Marjory Pompilus
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Malcolm Prior
- School of Medicine, University of Nottingham, Nottingham, UK
| | | | - Henning M Reimann
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Jonathan Reinwald
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Rodrigo Triana Del Rio
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | - Alejandro Rivera-Olvera
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | | | - Gabriele Russo
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
| | - Tobias J Rutten
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Rie Ryoke
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Markus Sack
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Piergiorgio Salvan
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Basavaraju G Sanganahalli
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Aileen Schroeter
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bhedita J Seewoo
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | | | - Aline Seuwen
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bowen Shi
- iHuman Institute, ShanghaiTech University, Shanghai, China
| | - Nikoloz Sirmpilatze
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Joanna A B Smith
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Corrie Smith
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Filip Sobczak
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Petteri J Stenroos
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Milou Straathof
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Sandra Strobelt
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Akira Sumiyoshi
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- National Institutes for Quantum Science and Technology, Chiba, Japan
| | - Kengo Takahashi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Maria E Torres-García
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Raul Tudela
- Group of Biomedical Imaging, Consorcio Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), University of Barcelona, Barcelona, Spain
| | - Monica van den Berg
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Kajo van der Marel
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Aran T B van Hout
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Roberta Vertullo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Benjamin Vidal
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Roël M Vrooman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Victora X Wang
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Isabel Wank
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - David J G Watson
- School of Life Sciences, University of Nottingham, Nottingham, UK
| | - Ting Yin
- Animal Imaging and Technology Section, Center for Biomedical Imaging, École polytechnique fédérale de Lausanne, Lausanne, Switzerland
| | - Yongzhi Zhang
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Stefan Zurbruegg
- Neurosciences Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Sophie Achard
- Inria, University Grenoble Alpes, CNRS, Grenoble, France
| | - Sarael Alcauter
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Dorothee P Auer
- School of Medicine, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Emmanuel L Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Jürgen Baudewig
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
| | - Christian F Beckmann
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Nicolau Beckmann
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Erwin L A Blezer
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | | | - Susann Boretius
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Sandrine Bouvard
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Eike Budinger
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
- Center for Behavioral Brain Sciences, Magdeburg, Germany
| | - Joseph D Buxbaum
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Diana Cash
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Victoria Chapman
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Kai-Hsiang Chuang
- Queensland Brain Institute and Centre for Advanced Imaging, University of Queensland, St. Lucia, QLD, Australia
| | | | - Bram F Coolen
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Jeffrey W Dalley
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Marc Dhenain
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Rick M Dijkhuizen
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Oscar Esteban
- Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Cornelius Faber
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Marcelo Febo
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Kirk W Feindel
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | - Gianluigi Forloni
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Jérémie Fouquet
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
| | - Eduardo A Garza-Villarreal
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Natalia Gass
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Jeffrey C Glennon
- Conway Institute of Biomedical and Biomolecular Sciences, School of Medicine, University College Dublin, Dublin, Ireland
| | - Alessandro Gozzi
- Functional Neuroimaging Laboratory, Center for Neuroscience and Cognitive Systems, Istituto Italiano di Tecnologia, Rovereto, Italy
| | - Olli Gröhn
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Andrew Harkin
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Arend Heerschap
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Xavier Helluy
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
- Department of Biopsychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany
| | - Kristina Herfert
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Judith R Homberg
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Danielle J Houwing
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Fahmeed Hyder
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | | | - Ileana O Jelescu
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Heidi Johansen-Berg
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gen Kaneko
- School of Arts & Sciences, University of Houston-Victoria, Victoria, TX, USA
| | - Ryuta Kawashima
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Shella D Keilholz
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Georgios A Keliris
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Clare Kelly
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- School of Psychology, Trinity College Dublin, Dublin, Ireland
- Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Christian Kerskens
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Trinity Centre for Biomedical Engineering, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Jibran Y Khokhar
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Peter C Kind
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
- Centre for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine, Bangalore, India
| | | | - Jason P Lerch
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- Department of Medical Biophysics, University of Toronto, Toronto, QC, Canada
| | - Monica A López-Hidalgo
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | | | - Fabien Marchand
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - Rogier B Mars
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gerardo Marsella
- Animal Care Unit, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Edoardo Micotti
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Emma Muñoz-Moreno
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Jamie Near
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Physical Sciences Platform, Sunnybrook Research Institute, Toronto, QC, Canada
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Willem M Otte
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
- Department of Pediatric Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Patricia Pais-Roldán
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine, Forschungszentrum Juelich, Juelich, Germany
| | - Wen-Ju Pan
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Roberto A Prado-Alcalá
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Gina L Quirarte
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jennifer Rodger
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Tim Rosenow
- Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Crawley, WA, Australia
| | - Cassandra Sampaio-Baptista
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- School of Psychology and Neuroscience, University of Glasgow, Glasgow, UK
| | - Alexander Sartorius
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Stephen J Sawiak
- Translational Neuroimaging Laboratory, Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Tom W J Scheenen
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
| | - Noam Shemesh
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Yen-Yu Ian Shih
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amir Shmuel
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- Department of Physiology, McGill University, Montreal, QC, Canada
| | - Guadalupe Soria
- Laboratory of Surgical Neuroanatomy, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Ron Stoop
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | | | - Sally M Till
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Nick Todd
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Annemie Van Der Linden
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Annette van der Toorn
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Geralda A F van Tilborg
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Christian Vanhove
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Andor Veltien
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marleen Verhoye
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Lydia Wachsmuth
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Wolfgang Weber-Fahr
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Patricia Wenk
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
| | - Xin Yu
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
| | - Valerio Zerbi
- Neuro-X Institute, School of Engineering (STI), EPFL, Lausanne, Switzerland
- Centre for Biomedical Imaging (CIBM), Lausanne, Switzerland
| | - Nanyin Zhang
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Baogui B Zhang
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Luc Zimmer
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
- CERMEP - Imagerie du vivant, Lyon, France
- Hospices Civils de Lyon, Lyon, France
| | - Gabriel A Devenyi
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - M Mallar Chakravarty
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Andreas Hess
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
10
|
Vicente-Rodríguez M, Mancuso R, Peris-Yague A, Simmons C, Gómez-Nicola D, Perry VH, Turkheimer F, Lovestone S, Parker CA, Cash D. Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. J Neuroinflammation 2023; 20:92. [PMID: 37032328 PMCID: PMC10084680 DOI: 10.1186/s12974-023-02769-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 03/20/2023] [Indexed: 04/11/2023] Open
Abstract
Neuroinflammation is an important component of many neurodegenerative diseases, whether as a primary cause or a secondary outcome. For that reason, either as diagnostic tools or to monitor progression and/or pharmacological interventions, there is a need for robust biomarkers of neuroinflammation in the brain. Mitochondrial TSPO (18 kDa Translocator protein) is one of few available biomarkers of neuroinflammation for which there are clinically available PET imaging agents. In this study, we further characterised neuroinflammation in a mouse model of prion-induced chronic neurodegeneration (ME7) including a pharmacological intervention via a CSF1R inhibitor. This was achieved by autoradiographic binding of the second-generation TSPO tracer, [3H]PBR28, along with a more comprehensive examination of the cellular contributors to the TSPO signal changes by immunohistochemistry. We observed regional increases of TSPO in the ME7 mouse brains, particularly in the hippocampus, cortex and thalamus. This increased TSPO signal was detected in the cells of microglia/macrophage lineage as well as in astrocytes, endothelial cells and neurons. Importantly, we show that the selective CSF1R inhibitor, JNJ-40346527 (JNJ527), attenuated the disease-dependent increase in TSPO signal, particularly in the dentate gyrus of the hippocampus, where JNJ527 attenuated the number of Iba1+ microglia and neurons, but not GFAP+ astrocytes or endothelial cells. These findings suggest that [3H]PBR28 quantitative autoradiography in combination with immunohistochemistry are important translational tools for detecting and quantifying neuroinflammation, and its treatments, in neurodegenerative disease. Furthermore, we demonstrate that although TSPO overexpression in the ME7 brains was driven by various cell types, the therapeutic effect of the CSF1R inhibitor was primarily to modulate TSPO expression in microglia and neurons, which identifies an important route of biological action of this particular CSF1R inhibitor and provides an example of a cell-specific effect of this type of therapeutic agent on the neuroinflammatory process.
Collapse
Affiliation(s)
- Marta Vicente-Rodríguez
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK.
- Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
| | - Renzo Mancuso
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
- Microglia and Inflammation in Neurological Disorders (MIND) Lab, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Biological Sciences, Southampton General Hospital, University of Southampton, Southampton, UK
| | - Alba Peris-Yague
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Camilla Simmons
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
| | - Diego Gómez-Nicola
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
- Biological Sciences, Southampton General Hospital, University of Southampton, Southampton, UK
| | - V Hugh Perry
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
- Biological Sciences, Southampton General Hospital, University of Southampton, Southampton, UK
| | - Federico Turkheimer
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
| | - Simon Lovestone
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
- Janssen Medical Ltd, High Wycombe, UK
| | - Christine A Parker
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
- GlaxoSmithKline, Stevenage, London, UK
| | - Diana Cash
- Department of Neuroimaging, BRAIN Centre (Biomarker Research and Imaging for Neuroscience), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA), London, UK
| |
Collapse
|
11
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023; 26:673-681. [PMID: 36973511 PMCID: PMC10493189 DOI: 10.1038/s41593-023-01286-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Accepted: 02/15/2023] [Indexed: 03/29/2023]
Abstract
Task-free functional connectivity in animal models provides an experimental framework to examine connectivity phenomena under controlled conditions and allows for comparisons with data modalities collected under invasive or terminal procedures. Currently, animal acquisitions are performed with varying protocols and analyses that hamper result comparison and integration. Here we introduce StandardRat, a consensus rat functional magnetic resonance imaging acquisition protocol tested across 20 centers. To develop this protocol with optimized acquisition and processing parameters, we initially aggregated 65 functional imaging datasets acquired from rats across 46 centers. We developed a reproducible pipeline for analyzing rat data acquired with diverse protocols and determined experimental and processing parameters associated with the robust detection of functional connectivity across centers. We show that the standardized protocol enhances biologically plausible functional connectivity patterns relative to previous acquisitions. The protocol and processing pipeline described here is openly shared with the neuroimaging community to promote interoperability and cooperation toward tackling the most important challenges in neuroscience.
Collapse
Affiliation(s)
- Joanes Grandjean
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands.
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
| | - Gabriel Desrosiers-Gregoire
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada
| | - Cynthia Anckaerts
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Diego Angeles-Valdez
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Fadi Ayad
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - David A Barrière
- UMR INRAE/CNRS 7247 Physiologie des Comportements et de la Reproduction, Physiologie de la reproduction et des comportements, Centre de recherche INRAE de Nouzilly, Tours, France
| | - Ines Blockx
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Aleksandra Bortel
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Margaret Broadwater
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Beatriz M Cardoso
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Marina Célestine
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Jorge E Chavez-Negrete
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Sangcheon Choi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Emma Christiaen
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Perrin Clavijo
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Luis Colon-Perez
- Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Samuel Cramer
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Tolomeo Daniele
- Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Elaine Dempsey
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Yujian Diao
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Laboratory for Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Arno Doelemeyer
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - David Dopfel
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Lenka Dvořáková
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Claudia Falfán-Melgoza
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Francisca F Fernandes
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Caitlin F Fowler
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
| | - Antonio Fuentes-Ibañez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Clément M Garin
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Eveline Gelderman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Carla E M Golden
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Chao C G Guo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Marloes J A G Henckens
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Lauren A Hennessy
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Peter Herman
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Nita Hofwijks
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Corey Horien
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Tudor M Ionescu
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Jolyon Jones
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Johannes Kaesser
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Eugene Kim
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Henriette Lambers
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Alberto Lazari
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Sung-Ho Lee
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amanda Lillywhite
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
| | - Yikang Liu
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Yanyan Y Liu
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Alejandra López-Castro
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Xavier López-Gil
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Zilu Ma
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Eilidh MacNicol
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Dan Madularu
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Center for Translational Neuroimaging, Northeastern University, Boston, MA, USA
| | - Francesca Mandino
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Sabina Marciano
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Matthew J McAuslan
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
| | - Patrick McCunn
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Alison McIntosh
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Xianzong Meng
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Lisa Meyer-Baese
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Stephan Missault
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Federico Moro
- Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Daphne M P Naessens
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Laura J Nava-Gomez
- Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, México
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | - Hiroi Nonaka
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Juan J Ortiz
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jaakko Paasonen
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Lore M Peeters
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Mickaël Pereira
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Pablo D Perez
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Marjory Pompilus
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Malcolm Prior
- School of Medicine, University of Nottingham, Nottingham, UK
| | | | - Henning M Reimann
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Jonathan Reinwald
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Rodrigo Triana Del Rio
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | - Alejandro Rivera-Olvera
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | | | - Gabriele Russo
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
| | - Tobias J Rutten
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Rie Ryoke
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Markus Sack
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Piergiorgio Salvan
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Basavaraju G Sanganahalli
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Aileen Schroeter
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bhedita J Seewoo
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | | | - Aline Seuwen
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bowen Shi
- iHuman Institute, ShanghaiTech University, Shanghai, China
| | - Nikoloz Sirmpilatze
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Joanna A B Smith
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Corrie Smith
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Filip Sobczak
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Petteri J Stenroos
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Milou Straathof
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Sandra Strobelt
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Akira Sumiyoshi
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- National Institutes for Quantum Science and Technology, Chiba, Japan
| | - Kengo Takahashi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Maria E Torres-García
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Raul Tudela
- Group of Biomedical Imaging, Consorcio Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), University of Barcelona, Barcelona, Spain
| | - Monica van den Berg
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Kajo van der Marel
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Aran T B van Hout
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Roberta Vertullo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Benjamin Vidal
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Roël M Vrooman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Victora X Wang
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Isabel Wank
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - David J G Watson
- School of Life Sciences, University of Nottingham, Nottingham, UK
| | - Ting Yin
- Animal Imaging and Technology Section, Center for Biomedical Imaging, École polytechnique fédérale de Lausanne, Lausanne, Switzerland
| | - Yongzhi Zhang
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Stefan Zurbruegg
- Neurosciences Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Sophie Achard
- Inria, University Grenoble Alpes, CNRS, Grenoble, France
| | - Sarael Alcauter
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Dorothee P Auer
- School of Medicine, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Emmanuel L Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Jürgen Baudewig
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
| | - Christian F Beckmann
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Nicolau Beckmann
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Erwin L A Blezer
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | | | - Susann Boretius
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Sandrine Bouvard
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Eike Budinger
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
- Center for Behavioral Brain Sciences, Magdeburg, Germany
| | - Joseph D Buxbaum
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Diana Cash
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Victoria Chapman
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Kai-Hsiang Chuang
- Queensland Brain Institute and Centre for Advanced Imaging, University of Queensland, St. Lucia, QLD, Australia
| | | | - Bram F Coolen
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Jeffrey W Dalley
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Marc Dhenain
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Rick M Dijkhuizen
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Oscar Esteban
- Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Cornelius Faber
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Marcelo Febo
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Kirk W Feindel
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | - Gianluigi Forloni
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Jérémie Fouquet
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
| | - Eduardo A Garza-Villarreal
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Natalia Gass
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Jeffrey C Glennon
- Conway Institute of Biomedical and Biomolecular Sciences, School of Medicine, University College Dublin, Dublin, Ireland
| | - Alessandro Gozzi
- Functional Neuroimaging Laboratory, Center for Neuroscience and Cognitive Systems, Istituto Italiano di Tecnologia, Rovereto, Italy
| | - Olli Gröhn
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Andrew Harkin
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Arend Heerschap
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Xavier Helluy
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
- Department of Biopsychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany
| | - Kristina Herfert
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Judith R Homberg
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Danielle J Houwing
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Fahmeed Hyder
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | | | - Ileana O Jelescu
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Heidi Johansen-Berg
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gen Kaneko
- School of Arts & Sciences, University of Houston-Victoria, Victoria, TX, USA
| | - Ryuta Kawashima
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Shella D Keilholz
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Georgios A Keliris
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Clare Kelly
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- School of Psychology, Trinity College Dublin, Dublin, Ireland
- Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Christian Kerskens
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Trinity Centre for Biomedical Engineering, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Jibran Y Khokhar
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Peter C Kind
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
- Centre for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine, Bangalore, India
| | | | - Jason P Lerch
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- Department of Medical Biophysics, University of Toronto, Toronto, QC, Canada
| | - Monica A López-Hidalgo
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | | | - Fabien Marchand
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - Rogier B Mars
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gerardo Marsella
- Animal Care Unit, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Edoardo Micotti
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Emma Muñoz-Moreno
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Jamie Near
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Physical Sciences Platform, Sunnybrook Research Institute, Toronto, QC, Canada
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Willem M Otte
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
- Department of Pediatric Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Patricia Pais-Roldán
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine, Forschungszentrum Juelich, Juelich, Germany
| | - Wen-Ju Pan
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Roberto A Prado-Alcalá
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Gina L Quirarte
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jennifer Rodger
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Tim Rosenow
- Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Crawley, WA, Australia
| | - Cassandra Sampaio-Baptista
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- School of Psychology and Neuroscience, University of Glasgow, Glasgow, UK
| | - Alexander Sartorius
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Stephen J Sawiak
- Translational Neuroimaging Laboratory, Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Tom W J Scheenen
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
| | - Noam Shemesh
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Yen-Yu Ian Shih
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amir Shmuel
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- Department of Physiology, McGill University, Montreal, QC, Canada
| | - Guadalupe Soria
- Laboratory of Surgical Neuroanatomy, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Ron Stoop
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | | | - Sally M Till
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Nick Todd
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Annemie Van Der Linden
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Annette van der Toorn
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Geralda A F van Tilborg
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Christian Vanhove
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Andor Veltien
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marleen Verhoye
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Lydia Wachsmuth
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Wolfgang Weber-Fahr
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Patricia Wenk
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
| | - Xin Yu
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
| | - Valerio Zerbi
- Neuro-X Institute, School of Engineering (STI), EPFL, Lausanne, Switzerland
- Centre for Biomedical Imaging (CIBM), Lausanne, Switzerland
| | - Nanyin Zhang
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Baogui B Zhang
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Luc Zimmer
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
- CERMEP - Imagerie du vivant, Lyon, France
- Hospices Civils de Lyon, Lyon, France
| | - Gabriel A Devenyi
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - M Mallar Chakravarty
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Andreas Hess
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
12
|
Barrett RLC, Cash D, Simmons C, Kim E, Wood TC, Stones R, Vernon AC, Catani M, Dell'Acqua F. Tissue optimization strategies for high-quality ex vivo diffusion imaging. NMR Biomed 2023; 36:e4866. [PMID: 36321360 PMCID: PMC10078604 DOI: 10.1002/nbm.4866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 09/09/2022] [Accepted: 10/03/2022] [Indexed: 06/16/2023]
Abstract
Ex vivo diffusion imaging can be used to study healthy and pathological tissue microstructure in the rodent brain with high resolution, providing a link between in vivo MRI and ex vivo microscopy techniques. Major challenges for the successful acquisition of ex vivo diffusion imaging data however are changes in the relaxivity and diffusivity of brain tissue following perfusion fixation. In this study we address this question by examining the combined effects of tissue preparation factors that influence signal-to-noise ratio (SNR) and consequently image quality, including fixative concentration, contrast agent concentration and tissue rehydration time. We present an optimization strategy combining these factors to manipulate theT 1 andT 2 of fixed tissue and maximize SNR efficiency. We apply this strategy in the rat brain, for a diffusion-weighted spin echo protocol with TE = 27 ms on a 9.4 T scanner with a 39 mm volume coil and 660 mT/m 114 mm gradient insert. We used a reduced fixative concentration of 2% paraformaldehyde (PFA), rehydration time more than 20 days, 15 mM Gd-DTPA in perfusate and TR 250 ms. This resulted in a doubling of SNR and an increase in SNR per unit time of 135% in cortical grey matter and 88% in white matter compared with 4% PFA and no contrast agent. This improved SNR efficiency enabled the acquisition of excellent-quality high-resolution (78 μ m isotropic voxel size) diffusion data with b = 4000 s/mm2 , 30 diffusion directions and a field of view of 40 × 13 × 18 mm3 in less than 4 days. It was also possible to achieve comparable data quality for a standard resolution (150 μ m) diffusion dataset in 2 1 4 h. In conclusion, the tissue optimization strategy presented here may be used to improve SNR, increase spatial resolution and/or allow faster acquisitions in preclinical ex vivo diffusion MRI experiments.
Collapse
Affiliation(s)
- Rachel L. C. Barrett
- NatBrainLab, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Tobias C. Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Richard Stones
- NatBrainLab, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Anthony C. Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology, and Neuroscience, King's College LondonUK
| | - Marco Catani
- NatBrainLab, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| | - Flavio Dell'Acqua
- NatBrainLab, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
- Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, King's College LondonUK
| |
Collapse
|
13
|
Bogado Lopes J, Senko AN, Bahnsen K, Geisler D, Kim E, Bernanos M, Cash D, Ehrlich S, Vernon AC, Kempermann G. Individual behavioral trajectories shape whole-brain connectivity in mice. eLife 2023; 12:e80379. [PMID: 36645260 PMCID: PMC9977274 DOI: 10.7554/elife.80379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 01/13/2023] [Indexed: 01/17/2023] Open
Abstract
It is widely assumed that our actions shape our brains and that the resulting connections determine who we are. To test this idea in a reductionist setting, in which genes and environment are controlled, we investigated differences in neuroanatomy and structural covariance by ex vivo structural magnetic resonance imaging in mice whose behavioral activity was continuously tracked for 3 months in a large, enriched environment. We confirmed that environmental enrichment increases mouse hippocampal volumes. Stratifying the enriched group according to individual longitudinal behavioral trajectories, however, revealed striking differences in mouse brain structural covariance in continuously highly active mice compared to those whose trajectories showed signs of habituating activity. Network-based statistics identified distinct subnetworks of murine structural covariance underlying these differences in behavioral activity. Together, these results reveal that differentiated behavioral trajectories of mice in an enriched environment are associated with differences in brain connectivity.
Collapse
Affiliation(s)
- Jadna Bogado Lopes
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| | - Anna N Senko
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| | - Klaas Bahnsen
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
| | - Daniel Geisler
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Michel Bernanos
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Stefan Ehrlich
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
- Department of Child and Adolescent Psychiatry, Faculty of Medicine, Eating Disorder Treatment and Research CenterDresdenGermany
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's CollegeLondonUnited Kingdom
- MRC Centre for Neurodevelopmental Disorders, King's CollegeLondonUnited Kingdom
| | - Gerd Kempermann
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| |
Collapse
|
14
|
Gnoni V, Wasserman D, Duncan I, Tsai CC, Cash D, Higgins S, Drakatos P, Nesbitt A, Leschziner G, O'Regan D, Rosenzweig I. Cognitive dysfunction in ‘pure’ OSA patients without any other comorbidities. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
15
|
Wood TC, Cash D, MacNicol E, Simmons C, Kim E, Lythgoe DJ, Zelaya F, Turkheimer F. Non-Invasive measurement of the cerebral metabolic rate of oxygen using MRI in rodents. Wellcome Open Res 2022; 6:109. [PMID: 36081865 PMCID: PMC9428501 DOI: 10.12688/wellcomeopenres.16734.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2022] [Indexed: 11/20/2022] Open
Abstract
Malfunctions of oxygen metabolism are suspected to play a key role in a number of neurological and psychiatric disorders, but this hypothesis cannot be properly investigated without an in-vivo non-invasive measurement of brain oxygen consumption. We present a new way to measure the Cerebral Metabolic Rate of Oxygen (CMRO2) by combining two existing magnetic resonance imaging techniques, namely arterial spin-labelling and oxygen extraction fraction mapping. This method was validated by imaging rats under different anaesthetic regimes and was strongly correlated to glucose consumption measured by autoradiography.
Collapse
Affiliation(s)
- Tobias C Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Eilidh MacNicol
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - David J Lythgoe
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Fernando Zelaya
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| |
Collapse
|
16
|
Wood TC, Cash D, MacNicol E, Simmons C, Kim E, Lythgoe DJ, Zelaya F, Turkheimer F. Non-Invasive measurement of the cerebral metabolic rate of oxygen using MRI in rodents. Wellcome Open Res 2022; 6:109. [PMID: 36081865 PMCID: PMC9428501 DOI: 10.12688/wellcomeopenres.16734.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2022] [Indexed: 08/17/2023] Open
Abstract
Malfunctions of oxygen metabolism are suspected to play a key role in a number of neurological and psychiatric disorders, but this hypothesis cannot be properly investigated without an in-vivo non-invasive measurement of brain oxygen consumption. We present a new way to measure the Cerebral Metabolic Rate of Oxygen (CMRO 2) by combining two existing magnetic resonance imaging techniques, namely arterial spin-labelling and oxygen extraction fraction mapping. This method was validated by imaging rats under different anaesthetic regimes and was strongly correlated to glucose consumption measured by autoradiography.
Collapse
Affiliation(s)
- Tobias C Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Eilidh MacNicol
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - David J Lythgoe
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Fernando Zelaya
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, UK
| |
Collapse
|
17
|
Wood TC, Cash D, MacNicol E, Simmons C, Kim E, Lythgoe DJ, Zelaya F, Turkheimer F. Non-Invasive measurement of the cerebral metabolic rate of oxygen using MRI in rodents. Wellcome Open Res 2022; 6:109. [DOI: 10.12688/wellcomeopenres.16734.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2022] [Indexed: 11/20/2022] Open
Abstract
Malfunctions of oxygen metabolism are suspected to play a key role in a number of neurological and psychiatric disorders, but this hypothesis cannot be properly investigated without an in-vivo non-invasive measurement of brain oxygen consumption. We present a new way to measure the Cerebral Metabolic Rate of Oxygen (CMRO2) by combining two existing magnetic resonance imaging techniques, namely arterial spin-labelling and oxygen extraction fraction mapping. This method was validated by imaging rats under different anaesthetic regimes and was strongly correlated to glucose consumption measured by autoradiography.
Collapse
|
18
|
Gelegen C, Cash D, Ilic K, Sander M, Kim E, Simmons C, Bernanos M, Lama J, Randall K, Brown JT, Kalanj-Bognar S, Cooke S, Ray Chaudhuri K, Ballard C, Francis P, Rosenzweig I. Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder. Sci Rep 2022; 12:7973. [PMID: 35562385 PMCID: PMC9105586 DOI: 10.1038/s41598-022-11516-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 04/22/2022] [Indexed: 11/29/2022] Open
Abstract
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a REM parasomnia that often predicts the later occurrence of alpha-synucleinopathies. Variants in the gene encoding for the lysosomal enzyme glucocerebrosidase, GBA, strongly increase the risk of RBD. In a GBA1-mouse model recently shown to mimic prodromal stages of α-synucleinopathy, we now demonstrate striking REM and NREM electroencephalographic sleep abnormalities accompanied by distinct structural changes in the more widespread sleep neurocircuitry.
Collapse
Affiliation(s)
- Cigdem Gelegen
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- Basic and Clinical Neuroscience, IoPPN, KCL, London, UK
| | - Diana Cash
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- BRAIN, Department of Neuroimaging, KCL, London, UK
| | - Katarina Ilic
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Millie Sander
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Eugene Kim
- BRAIN, Department of Neuroimaging, KCL, London, UK
| | | | | | - Joana Lama
- Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Diseases, Guy's Campus, KCL, London, UK
| | | | - Jonathan T Brown
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Svjetlana Kalanj-Bognar
- Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Samuel Cooke
- Basic and Clinical Neuroscience, IoPPN, KCL, London, UK
| | - K Ray Chaudhuri
- King's College London and Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK
| | - Clive Ballard
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Paul Francis
- College of Medicine and Health, University of Exeter, Exeter, UK
- Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Diseases, Guy's Campus, KCL, London, UK
| | - Ivana Rosenzweig
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK.
- Sleep Disorders Centre, GSTT, London, UK.
| |
Collapse
|
19
|
Serrano ME, Kim E, Petrinovic MM, Turkheimer F, Cash D. Imaging Synaptic Density: The Next Holy Grail of Neuroscience? Front Neurosci 2022; 16:796129. [PMID: 35401097 PMCID: PMC8990757 DOI: 10.3389/fnins.2022.796129] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Accepted: 02/15/2022] [Indexed: 12/19/2022] Open
Abstract
The brain is the central and most complex organ in the nervous system, comprising billions of neurons that constantly communicate through trillions of connections called synapses. Despite being formed mainly during prenatal and early postnatal development, synapses are continually refined and eliminated throughout life via complicated and hitherto incompletely understood mechanisms. Failure to correctly regulate the numbers and distribution of synapses has been associated with many neurological and psychiatric disorders, including autism, epilepsy, Alzheimer’s disease, and schizophrenia. Therefore, measurements of brain synaptic density, as well as early detection of synaptic dysfunction, are essential for understanding normal and abnormal brain development. To date, multiple synaptic density markers have been proposed and investigated in experimental models of brain disorders. The majority of the gold standard methodologies (e.g., electron microscopy or immunohistochemistry) visualize synapses or measure changes in pre- and postsynaptic proteins ex vivo. However, the invasive nature of these classic methodologies precludes their use in living organisms. The recent development of positron emission tomography (PET) tracers [such as (18F)UCB-H or (11C)UCB-J] that bind to a putative synaptic density marker, the synaptic vesicle 2A (SV2A) protein, is heralding a likely paradigm shift in detecting synaptic alterations in patients. Despite their limited specificity, novel, non-invasive magnetic resonance (MR)-based methods also show promise in inferring synaptic information by linking to glutamate neurotransmission. Although promising, all these methods entail various advantages and limitations that must be addressed before becoming part of routine clinical practice. In this review, we summarize and discuss current ex vivo and in vivo methods of quantifying synaptic density, including an evaluation of their reliability and experimental utility. We conclude with a critical assessment of challenges that need to be overcome before successfully employing synaptic density biomarkers as diagnostic and/or prognostic tools in the study of neurological and neuropsychiatric disorders.
Collapse
Affiliation(s)
- Maria Elisa Serrano
- Department of Neuroimaging, The BRAIN Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.,Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom
| | - Eugene Kim
- Department of Neuroimaging, The BRAIN Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.,Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom
| | - Marija M Petrinovic
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.,MRC Centre for Neurodevelopmental Disorders, King's College London, London, United Kingdom
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, The BRAIN Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.,Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom
| |
Collapse
|
20
|
Kiemes A, Gomes FV, Cash D, Uliana DL, Simmons C, Singh N, Vernon AC, Turkheimer F, Davies C, Stone JM, Grace AA, Modinos G. GABA A and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia. Neuropsychopharmacology 2022; 47:687-695. [PMID: 34743200 PMCID: PMC8782908 DOI: 10.1038/s41386-021-01213-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 10/09/2021] [Accepted: 10/13/2021] [Indexed: 01/19/2023]
Abstract
Hippocampal hyperactivity driven by GABAergic interneuron deficits and NMDA receptor hypofunction is associated with the hyperdopaminergic state often observed in schizophrenia. Furthermore, previous research in the methylazoxymethanol acetate (MAM) rat model has demonstrated that repeated peripubertal diazepam administration can prevent the emergence of adult hippocampal hyperactivity, dopamine-system hyperactivity, and associated psychosis-relevant behaviors. Here, we sought to characterize hippocampal GABAA and NMDA receptors in MAM-treated rats and to elucidate the receptor mechanisms underlying the promising effects of peripubertal diazepam exposure. Quantitative receptor autoradiography was used to measure receptor density in the dorsal hippocampus CA1, ventral hippocampus CA1, and ventral subiculum. Specifically, [3H]-Ro15-4513 was used to quantify the density of α5GABAA receptors (α5GABAAR), [3H]-flumazenil to quantify α1-3;5GABAAR, and [3H]-MK801 to quantify NMDA receptors. MAM rats exhibited anxiety and schizophrenia-relevant behaviors as measured by elevated plus maze and amphetamine-induced hyperlocomotion (AIH), although diazepam only partially rescued these behaviors. α5GABAAR density was reduced in MAM-treated rats in all hippocampal sub-regions, and negatively correlated with AIH. Ventral hippocampus CA1 α5GABAAR density was positively correlated with anxiety-like behavior. Dorsal hippocampus CA1 NMDA receptor density was increased in MAM-treated rats, and positively correlated with AIH. [3H]-flumazenil revealed no significant effects. Finally, we found no significant effect of diazepam treatment on receptor densities, potentially related to the only partial rescue of schizophrenia-relevant phenotypes. Overall, our findings provide first evidence of α5GABAAR and NMDA receptor abnormalities in the MAM model, suggesting that more selective pharmacological agents may become a novel therapeutic mechanism in schizophrenia.
Collapse
Affiliation(s)
- Amanda Kiemes
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
| | - Felipe V Gomes
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Daniela L Uliana
- Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Nisha Singh
- Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- MRC Centre for Neurodevelopmental Disorders, King's College London, London, UK
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Cathy Davies
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - James M Stone
- Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - Anthony A Grace
- Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Gemma Modinos
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- MRC Centre for Neurodevelopmental Disorders, King's College London, London, UK
| |
Collapse
|
21
|
Drakatos P, Olaithe M, Verma D, Ilic K, Cash D, Fatima Y, Higgins S, Young AH, Chaudhuri KR, Steier J, Skinner T, Bucks R, Rosenzweig I. Periodic limb movements during sleep: a narrative review. J Thorac Dis 2022; 13:6476-6494. [PMID: 34992826 PMCID: PMC8662505 DOI: 10.21037/jtd-21-1353] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 10/20/2021] [Indexed: 01/02/2023]
Abstract
Objective Using narrative review techniques, this paper evaluates the evidence for separable underlying patho-mechanisms of periodic limb movements (PLMs) to separable PLM motor patterns and phenotypes, in order to elucidate potential new treatment modalities. Background Periodic limb movement disorder (PLMD) is estimated to occur in 5–8% of the paediatric population and 4–11% of the general adult population. Due to significant sleep fragmentation, PLMD can lead to functional impairment, including hyperactivity and delayed language development in children, and poor concentration and work performance in adults. Longitudinal data demonstrate that those with PLMD are at greater risk of depression and anxiety, and a 4-fold greater risk of developing dementia. PLMD has been extensively studied over the past two decades, and several key insights into the genetic, pathophysiological, and neural correlates have been proposed. Amongst these proposals is the concept of separable PLM phenotypes, proposed on the basis of nocturnal features such as the ratio of limb movements and distribution throughout the night. PLM phenotype and presentation, however, varies significantly depending on the scoring utilized and the nocturnal features examined, across age, and co-morbid clinical conditions. Furthermore, associations between these phenotypes with major neurologic and psychiatric disorders remain controversial. Methods In order to elucidate potential divergent biological pathways that may help clarify important new treatment modalities, this paper utilizes narrative review and evaluates the evidence linking PLM motor patterns and phenotypes with hypothesised underlying patho-mechanisms. Distinctive, underlying patho-mechanisms include: a pure motor mechanism originating in the spinal cord, iron deficiency, dopamine system dysfunction, thalamic glutamatergic hyperactivity, and a more cortical-subcortical interplay. In support of the latter hypothesis, PLM rhythmicity appears tightly linked to the microarchitecture of sleep, not dissimilarly to the apnoeic/hypopneic events seen in obstructive sleep apnea (OSA). Conclusions This review closes with a proposal for greater investigation into the identification of potential, divergent biological pathways. To do so would require prospective, multimodal imaging clinical studies which may delineate differential responses to treatment in restless legs syndrome (RLS) without PLMS and PLMS without RLS. This could pave the way toward important new treatment modalities.
Collapse
Affiliation(s)
- Panagis Drakatos
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' Hospital, GSTT NHS, London, UK.,Faculty of Life and Sciences Medicine, King's College London, London, UK
| | - Michelle Olaithe
- School of Psychological Science, University of Western Australia, Perth, Western Australia, Australia
| | - Dhun Verma
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK
| | - Katarina Ilic
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK.,BRAIN, Imaging Centre, CNS, King's College London, London, UK
| | - Diana Cash
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK.,BRAIN, Imaging Centre, CNS, King's College London, London, UK
| | - Yaqoot Fatima
- Institute for Social Science Research, University of Queensland, Brisbane, Australia.,Centre for Rural and Remote Health, James Cook University, Mount Isa, Australia
| | - Sean Higgins
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' Hospital, GSTT NHS, London, UK
| | - Allan H Young
- School of Academic Psychiatry, King's College London, London, UK
| | - K Ray Chaudhuri
- King's College London and Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK
| | - Joerg Steier
- Sleep Disorders Centre, Guy's and St Thomas' Hospital, GSTT NHS, London, UK.,Faculty of Life and Sciences Medicine, King's College London, London, UK
| | - Timothy Skinner
- Institute of Psychology, University of Copenhagen, Copenhagen, Denmark.,La Trobe Rural Health School, La Trobe University, Bendigo, Victoria, Australia
| | - Romola Bucks
- School of Psychological Science, University of Western Australia, Perth, Western Australia, Australia.,The Raine Study, University of Western Australia, Perth, Australia
| | - Ivana Rosenzweig
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' Hospital, GSTT NHS, London, UK
| |
Collapse
|
22
|
MacNicol E, Wright P, Kim E, Brusini I, Esteban O, Simmons C, Turkheimer FE, Cash D. Age-Specific Adult Rat Brain MRI Templates and Tissue Probability Maps. Front Neuroinform 2022; 15:669049. [PMID: 35069163 PMCID: PMC8777032 DOI: 10.3389/fninf.2021.669049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 12/03/2021] [Indexed: 11/30/2022] Open
Abstract
Age-specific resources in human MRI mitigate processing biases that arise from structural changes across the lifespan. There are fewer age-specific resources for preclinical imaging, and they only represent developmental periods rather than adulthood. Since rats recapitulate many facets of human aging, it was hypothesized that brain volume and each tissue's relative contribution to total brain volume would change with age in the adult rat. Data from a longitudinal study of rats at 3, 5, 11, and 17 months old were used to test this hypothesis. Tissue volume was estimated from high resolution structural images using a priori information from tissue probability maps. However, existing tissue probability maps generated inaccurate gray matter probabilities in subcortical structures, particularly the thalamus. To address this issue, gray matter, white matter, and CSF tissue probability maps were generated by combining anatomical and signal intensity information. The effects of age on volumetric estimations were then assessed with mixed-effects models. Results showed that herein estimation of gray matter volumes better matched histological evidence, as compared to existing resources. All tissue volumes increased with age, and the tissue proportions relative to total brain volume varied across adulthood. Consequently, a set of rat brain templates and tissue probability maps from across the adult lifespan is released to expand the preclinical MRI community's fundamental resources.
Collapse
Affiliation(s)
- Eilidh MacNicol
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Paul Wright
- School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Irene Brusini
- Department of Biomedical Engineering and Health Systems, KTH Royal Institute of Technology, Stockholm, Sweden
- Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
| | - Oscar Esteban
- Department of Psychology, Stanford University, Stanford, CA, United States
- Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Federico E. Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| |
Collapse
|
23
|
Brusini I, MacNicol E, Kim E, Smedby Ö, Wang C, Westman E, Veronese M, Turkheimer F, Cash D. MRI-derived brain age as a biomarker of ageing in rats: validation using a healthy lifestyle intervention. Neurobiol Aging 2022; 109:204-215. [PMID: 34775211 DOI: 10.1016/j.neurobiolaging.2021.10.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 10/06/2021] [Accepted: 10/08/2021] [Indexed: 12/21/2022]
Abstract
The difference between brain age predicted from MRI and chronological age (the so-called BrainAGE) has been proposed as an ageing biomarker. We analyse its cross-species potential by testing it on rats undergoing an ageing modulation intervention. Our rat brain age prediction model combined Gaussian process regression with a classifier and achieved a mean absolute error (MAE) of 4.87 weeks using cross-validation on a longitudinal dataset of 31 normal ageing rats. It was then tested on two groups of 24 rats (MAE = 9.89 weeks, correlation coefficient = 0.86): controls vs. a group under long-term environmental enrichment and dietary restriction (EEDR). Using a linear mixed-effects model, BrainAGE was found to increase more slowly with chronological age in EEDR rats (p=0.015 for the interaction term). Cox regression showed that older BrainAGE at 5 months was associated with higher mortality risk (p=0.03). Our findings suggest that lifestyle-related prevention approaches may help to slow down brain ageing in rodents and the potential of BrainAGE as a predictor of age-related health outcomes.
Collapse
Affiliation(s)
- Irene Brusini
- Department of Biomedical Engineering and Health Systems,KTH Royal Institute of Technology, Stockholm, Sweden; Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
| | - Eilidh MacNicol
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Örjan Smedby
- Department of Biomedical Engineering and Health Systems,KTH Royal Institute of Technology, Stockholm, Sweden
| | - Chunliang Wang
- Department of Biomedical Engineering and Health Systems,KTH Royal Institute of Technology, Stockholm, Sweden
| | - Eric Westman
- Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; Department of Information Engineering, University of Padua, Padua, Italy
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| |
Collapse
|
24
|
Frison M, Faccenda D, Abeti R, Rigon M, Strobbe D, England-Rendon BS, Cash D, Barnes K, Sadeghian M, Sajic M, Wells LA, Xia D, Giunti P, Smith K, Mortiboys H, Turkheimer FE, Campanella M. The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity. Mol Psychiatry 2021; 26:2721-2739. [PMID: 33664474 PMCID: PMC8505241 DOI: 10.1038/s41380-021-01050-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 01/13/2021] [Accepted: 02/05/2021] [Indexed: 12/14/2022]
Abstract
Dysfunctional mitochondria characterise Parkinson's Disease (PD). Uncovering etiological molecules, which harm the homeostasis of mitochondria in response to pathological cues, is therefore pivotal to inform early diagnosis and therapy in the condition, especially in its idiopathic forms. This study proposes the 18 kDa Translocator Protein (TSPO) to be one of those. Both in vitro and in vivo data show that neurotoxins, which phenotypically mimic PD, increase TSPO to enhance cellular redox-stress, susceptibility to dopamine-induced cell death, and repression of ubiquitin-dependent mitophagy. TSPO amplifies the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signalling, forming positive feedback, which represses the transcription factor EB (TFEB) and the controlled production of lysosomes. Finally, genetic variances in the transcriptome confirm that TSPO is required to alter the autophagy-lysosomal pathway during neurotoxicity.
Collapse
Affiliation(s)
- Michele Frison
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom
- MRC Mitochondrial Biology Unit, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Danilo Faccenda
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom
| | - Rosella Abeti
- Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square London, United Kingdom
| | - Manuel Rigon
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom
- Department of Biology, University of Rome TorVergata, Via della Ricerca Scientifica, Rome, Italy
| | - Daniela Strobbe
- Department of Biology, University of Rome TorVergata, Via della Ricerca Scientifica, Rome, Italy
| | - Britannie S England-Rendon
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, King's College London, Camberwell, United Kingdom
| | - Katy Barnes
- Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom
| | - Mona Sadeghian
- Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Marija Sajic
- Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Lisa A Wells
- Imanova Limited, Centre for Imaging Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom
| | - Dong Xia
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom
| | - Paola Giunti
- Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square London, United Kingdom
| | - Kenneth Smith
- Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Heather Mortiboys
- Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom
| | - Federico E Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, King's College London, Camberwell, United Kingdom
| | - Michelangelo Campanella
- Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, Royal College Street, London, United Kingdom.
- Department of Biology, University of Rome TorVergata, Via della Ricerca Scientifica, Rome, Italy.
- University College London Consortium for Mitochondrial Research, London, United Kingdom.
| |
Collapse
|
25
|
Lin Z, Kim E, Ahmed M, Han G, Simmons C, Redhead Y, Bartlett J, Pena Altamira LE, Callaghan I, White MA, Singh N, Sawiak S, Spires-Jones T, Vernon AC, Coleman MP, Green J, Henstridge C, Davies JS, Cash D, Sreedharan J. MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Commun 2021; 3:fcab114. [PMID: 34136812 PMCID: PMC8204366 DOI: 10.1093/braincomms/fcab114] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 04/13/2021] [Accepted: 04/17/2021] [Indexed: 01/01/2023] Open
Abstract
Amyotrophic lateral sclerosis and frontotemporal dementia are overlapping diseases in which MRI reveals brain structural changes in advance of symptom onset. Recapitulating these changes in preclinical models would help to improve our understanding of the molecular causes underlying regionally selective brain atrophy in early disease. We therefore investigated the translational potential of the TDP-43Q331K knock-in mouse model of amyotrophic lateral sclerosis-frontotemporal dementia using MRI. We performed in vivo MRI of TDP-43Q331K knock-in mice. Regions of significant volume change were chosen for post-mortem brain tissue analyses. Ex vivo computed tomography was performed to investigate skull shape. Parvalbumin neuron density was quantified in post-mortem amyotrophic lateral sclerosis frontal cortex. Adult mutants demonstrated parenchymal volume reductions affecting the frontal lobe and entorhinal cortex in a manner reminiscent of amyotrophic lateral sclerosis-frontotemporal dementia. Subcortical, cerebellar and brain stem regions were also affected in line with observations in pre-symptomatic carriers of mutations in C9orf72, the commonest genetic cause of both amyotrophic lateral sclerosis and frontotemporal dementia. Volume loss was also observed in the dentate gyrus of the hippocampus, along with ventricular enlargement. Immunohistochemistry revealed reduced parvalbumin interneurons as a potential cellular correlate of MRI changes in mutant mice. By contrast, microglia was in a disease activated state even in the absence of brain volume loss. A reduction in immature neurons was found in the dentate gyrus, indicative of impaired adult neurogenesis, while a paucity of parvalbumin interneurons in P14 mutant mice suggests that TDP-43Q331K disrupts neurodevelopment. Computerized tomography imaging showed altered skull morphology in mutants, further suggesting a role for TDP-43Q331K in development. Finally, analysis of human post-mortem brains confirmed a paucity of parvalbumin interneurons in the prefrontal cortex in sporadic amyotrophic lateral sclerosis and amyotrophic lateral sclerosis linked to C9orf72 mutations. Regional brain MRI changes seen in human amyotrophic lateral sclerosis-frontotemporal dementia are recapitulated in TDP-43Q331K knock-in mice. By marrying in vivo imaging with targeted histology, we can unravel cellular and molecular processes underlying selective brain vulnerability in human disease. As well as helping to understand the earliest causes of disease, our MRI and histological markers will be valuable in assessing the efficacy of putative therapeutics in TDP-43Q331K knock-in mice.
Collapse
Affiliation(s)
- Ziqiang Lin
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
- West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Eugene Kim
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King’s College London, London SE5 9NU, UK
| | - Mohi Ahmed
- Centre for Craniofacial and Regenerative Biology, Floor 27 Tower Wing, Guy’s Hospital, King’s College London, London SE1 9RT, UK
| | - Gang Han
- Molecular Neurobiology Group, Institute of Life Sciences, School of Medicine, Swansea University, Swansea SA2 8PP, UK
| | - Camilla Simmons
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King’s College London, London SE5 9NU, UK
| | - Yushi Redhead
- Centre for Craniofacial and Regenerative Biology, Floor 27 Tower Wing, Guy’s Hospital, King’s College London, London SE1 9RT, UK
| | - Jack Bartlett
- Molecular Neurobiology Group, Institute of Life Sciences, School of Medicine, Swansea University, Swansea SA2 8PP, UK
| | - Luis Emiliano Pena Altamira
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
| | - Isobel Callaghan
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
| | - Matthew A White
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
| | - Nisha Singh
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King’s College London, London SE5 9NU, UK
- School of Biomedical Engineering & Imaging Sciences, St Thomas' Hospital, King's College London, 4th floor Lambeth Wing, London SE1 7EH, UK
| | - Stephen Sawiak
- Department of Clinical Neurosciences, Cambridge University, Cambridge CB2 0QQ, UK
| | - Tara Spires-Jones
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
| | | | - Jeremy Green
- Centre for Craniofacial and Regenerative Biology, Floor 27 Tower Wing, Guy’s Hospital, King’s College London, London SE1 9RT, UK
| | - Christopher Henstridge
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
- Division of Systems Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, UK
| | - Jeffrey S Davies
- Molecular Neurobiology Group, Institute of Life Sciences, School of Medicine, Swansea University, Swansea SA2 8PP, UK
| | - Diana Cash
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King’s College London, London SE5 9NU, UK
| | - Jemeen Sreedharan
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London SE5 9RT, UK
| |
Collapse
|
26
|
Wood TC, Cash D, MacNicol E, Simmons C, Kim E, Lythgoe DJ, Zelaya F, Turkheimer F. Non-Invasive measurement of the cerebral metabolic rate of oxygen using MRI in rodents. Wellcome Open Res 2021; 6:109. [DOI: 10.12688/wellcomeopenres.16734.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/05/2021] [Indexed: 11/20/2022] Open
Abstract
Malfunctions of oxygen metabolism are suspected to play a key role in a number of neurological and psychiatric disorders, but this hypothesis cannot be properly investigated without an in-vivo non-invasive measurement of brain oxygen consumption. We present a new way to measure the Cerebral Metabolic Rate of Oxygen (CMRO2) by combining two existing magnetic resonance imaging techniques, namely arterial spin-labelling and oxygen extraction fraction mapping. This method was validated by imaging rats under different anaesthetic regimes and was strongly correlated to glucose consumption measured by autoradiography.
Collapse
|
27
|
Basalay MV, Wiart M, Chauveau F, Dumot C, Leon C, Amaz C, Bolbos R, Cash D, Kim E, Mechtouff L, Cho TH, Nighoghossian N, Davidson SM, Ovize M, Yellon DM. Abstract P752: Neuroprotection by Remote Ischemic Conditioning in the Setting of Acute Ischemic Stroke: A Preclinical Two-Centre International Study. Stroke 2021. [DOI: 10.1161/str.52.suppl_1.p752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose:
Currently, reperfusion is the only existing treatment strategy for patients with acute ischemic stroke. However, reperfusion may cause further brain damage. One of the feasible therapies targeting reperfusion injury is remote ischemic conditioning (RIC).
The main objective of this study was to test the neuroprotective effects of RIC in a rat model of acute ischemic stroke in a randomized and blinded two-centre MRI study with a priori sample size calculation
.
Methods:
Eighty male Sprague Dawley rats underwent 90-min middle cerebral artery occlusion. Multiparametric MRI was performed per-occlusion to ascertain focal cerebral ischemia (inclusion criteria) and to control interindividual variability in the analysis. RIC was started 10 min before reperfusion, and consisted of 4 cycles of 5-min left hind limb ischemia. The primary endpoint of the study was infarct size measured on T2-weighted MRI at 24h, corrected for edema, and
expressed as percentage of the area-at-risk of infarction
. Secondary endpoints were hemispheric space-modifying edema, infarct growth between per-occlusion and 24h MRI, and neurofunctional outcome measured by neuroscores.
Results:
Two animals died in each group. In total, 47 rats were included in the analysis after applying the pre-defined inclusion criteria (23 in control group and 24 in RIC group). Infarct size was significantly reduced in the RIC group (mean, interquartile range: 19% [8% ; 32%] vs control: 40% [17% ; 59%], p=0.028). This infarct-limiting effect was still statistically significant after adjustment for apparent diffusion coefficient (ADC) lesion size in multivariate analysis. In the subgroup of rats with ADC lesion > 100 mm3, infarct size reduced from 58% [40%; 66%] to 32% [27%; 40%], p=0.004. In line with this result, RIC significantly improved neuroscores (6 [3 ; 8] vs control: 9 [7 ; 11], p=0.032). The other secondary endpoints were not statistically different between groups.
Conclusions:
RIC in the setting of acute stroke in rats is safe, reduces infarct size and improves functional recovery in a two-centre international study using translational imaging endpoints.
Collapse
Affiliation(s)
| | - Marlene Wiart
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Lyon, France
| | - Fabien Chauveau
- Université Lyon, Lyon Neuroscience Rsch Cntr, CNRS UMR5292, Inserm U1028, Lyon, France
| | - Chloe Dumot
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Lyon, France
| | - Christelle Leon
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Lyon, France
| | - Camille Amaz
- Clinical Investigation Cntr, CIC 1407, HCL, Louis Pradel Hosp, Lyon, France
| | | | - Diana Cash
- Dept of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, James Black Cntr, London, United Kingdom
| | - Eugene Kim
- Dept of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, James Black Cntr, London, United Kingdom
| | - Laura Mechtouff
- Stroke department, Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon; Hospices Civils de Lyon, Lyon, France
| | - Tae-Hee Cho
- Stroke department, Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon; Hospices Civils de Lyon, Lyon, France
| | - Norbert Nighoghossian
- Stroke department, Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon; Hospices Civils de Lyon, Lyon, France
| | | | - Michel Ovize
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Lyon, France
| | - Derek M Yellon
- The Hatter Cardiovascular Institute, London, United Kingdom
| |
Collapse
|
28
|
Gnoni V, Ilic K, Drakatos P, Petrinovic MM, Cash D, Steier J, Morrell MJ, Petanjek Z, Kalanj-Bognar S, Rosenzweig I. Obstructive sleep apnea and multiple facets of a neuroinflammatory response: a narrative review. J Thorac Dis 2021; 14:564-574. [PMID: 35280483 PMCID: PMC8902117 DOI: 10.21037/jtd-21-1231] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Accepted: 12/20/2021] [Indexed: 11/06/2022]
Abstract
Background Obstructive sleep apnea (OSA) is a chronic, highly prevalent, multi-system and sleep disorder, which may contribute to cognitive impairment and a variety of structural and neurophysiologic changes. The focus on OSA is warranted given its recognized links with major psychiatric and neurologic disorders, including Alzheimer’s disease. Some preliminary studies suggest a dual effect of the inflammatory response in OSA. Neuroinflammation may present with initial, potentially adaptive and homeostatic, and later, a more distinctly maladaptive, precipitating and perpetuating role. Objective We here propose and argue in favour of the inflammatory process in the brain as a likely binding mechanism behind at least some effects that OSA may have on the brain and its function. Several OSA-triggered molecular and cellular events, that could lead to a neurodegenerative cascade, are similarly discussed. Methods This perspective reviews the body of literature that investigates potential links between the inflammatory processes in the brain and the OSA. A special emphasis is placed on a potential role for neuroplastin, a novel transmembrane synaptic protein involved in the neuroplasticity and known to be differentially regulated in the OSA. Conclusions The intricate interplay between neuroinflammation and other mechanistic correlates of OSA add to the evidence that neuroinflammation may be a key target for future therapeutic strategies in a number of comorbid disorders. The future studies will need to answer whether it is sleep fragmentation (SF) or intermittent hypoxia (IH) which may drive any such neuroinflammation.
Collapse
Affiliation(s)
- Valentina Gnoni
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- Sleep Disorders Centre, Guy’s and St Thomas’ Hospital, GSTT NHS, London, UK
| | - Katarina Ilic
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- BRAIN, Imaging Centre, CNS, King’s College London, UK
- Croatian Institute for Brain Research, Centre for Excellence (HIIM), University of Zagreb School of Medicine, Zagreb, Croatia
| | - Panagis Drakatos
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- Sleep Disorders Centre, Guy’s and St Thomas’ Hospital, GSTT NHS, London, UK
- Faculty of Life and Sciences Medicine, King’s College London, UK
| | - Marija M. Petrinovic
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
| | - Diana Cash
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- BRAIN, Imaging Centre, CNS, King’s College London, UK
| | - Joerg Steier
- Sleep Disorders Centre, Guy’s and St Thomas’ Hospital, GSTT NHS, London, UK
- Faculty of Life and Sciences Medicine, King’s College London, UK
| | - Mary J. Morrell
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- National Heart and Lung Institute, Imperial College London, London, UK
- Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Zdravko Petanjek
- Croatian Institute for Brain Research, Centre for Excellence (HIIM), University of Zagreb School of Medicine, Zagreb, Croatia
| | - Svjetlana Kalanj-Bognar
- Croatian Institute for Brain Research, Centre for Excellence (HIIM), University of Zagreb School of Medicine, Zagreb, Croatia
| | - Ivana Rosenzweig
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King’s College London, UK
- Sleep Disorders Centre, Guy’s and St Thomas’ Hospital, GSTT NHS, London, UK
| |
Collapse
|
29
|
Wasserman D, Bindman D, Nesbitt AD, Cash D, Milosevic M, Francis PT, Chaudhuri KR, Leschziner GD, Ferini-Strambi L, Ballard C, Eccles A, Rosenzweig I. Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. Nat Sci Sleep 2021; 13:1-9. [PMID: 33447113 PMCID: PMC7802085 DOI: 10.2147/nss.s267037] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 11/02/2020] [Indexed: 01/03/2023] Open
Abstract
INTRODUCTION Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is increasingly recognised as an important precursor disease state of alpha-synucleinopathies. This parasomnia is characterized by a history of recurrent nocturnal dream enactment behaviour, loss of skeletal muscle atonia, and increased phasic muscle activity during REM sleep. Neuroimaging studies of striatal dopamine transporter uptake tracer signaling suggest increasing dopaminergic deficit across the continuum of the alpha-synucleinopathies, with early sleep dysfunction suggestive of early caudate dysfunction. Henceforth, we set out to investigate the relationship between early sleep changes and the striatal dopaminergic availability in iRBD. METHODS Twelve patients with iRBD, who had undergone a video polysomnography and a neuroimaging assessment of striatal dopamine transporter (DaT) uptake tracer signaling, and 22 matched controls who had similarly undergone a video polysomnography were retrospectively identified. Data were statistically analyzed to identify altered sleep parameters and correlate them with striatal dopamine transporter uptake tracer signaling. RESULTS The iRBD patients exhibited an increased number of periodic limb movements during sleep (P=0.001), compared to 22 age-matched healthy subjects. In addition, several significant links were found between regional DaT-uptakes and sleep architecture. Correlational analyses suggested a strong positive association between sleep fragmentation and dopamine deficiency in left caudate (r=-0.630, P=0.028), whilst an increased uptake in the whole striatum was strongly linked to the sleep efficiency, and to a lesser degree to the length of sleep duration. DISCUSSION To the best of our knowledge, this is the first demonstration of a close relationship between dopaminergic availability in striatum and the quality of sleep in iRBD. Taken together, our exploratory findings suggest that subtle but functionally significant striatal changes in early stages of iRBD may contribute to the further shaping of sleep architecture.
Collapse
Affiliation(s)
- Danielle Wasserman
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Dorothea Bindman
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK
| | - Alexander D Nesbitt
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.,Headache Group, Department of Clinical Neurosciences, King's College Hospital NHS Foundation Trust, London, UK
| | - Diana Cash
- BRAIN, Department of Neuroimaging, King's College London, London, UK
| | - Milan Milosevic
- School of Public Health "Andrija Stampar", University of Zagreb School of Medicine, Zagreb, Croatia
| | - Paul T Francis
- Wolfson Centre for Age-Related Diseases, King's College London, London, UK
| | - K Ray Chaudhuri
- Movement Disorders Unit, King's College Hospital, Department of Clinical and Basic Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, Parkinson Foundation Centre of Excellence, King's College London, London, UK
| | - Guy D Leschziner
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Luigi Ferini-Strambi
- Sleep Disorders Center, Department of Clinical Neurosciences, Università Vita-Salute San Raffaele, Milan, Italy
| | | | - Amy Eccles
- Department of Nuclear Medicine, Guy's and St. Thomas' NHS Foundation Trust, London, UK
| | - Ivana Rosenzweig
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.,Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| |
Collapse
|
30
|
Peris-Yague A, Kiemes A, Cash D, Cotel MC, Singh N, Vernon AC, Modinos G. Region-specific and dose-specific effects of chronic haloperidol exposure on [ 3H]-flumazenil and [ 3H]-Ro15-4513 GABA A receptor binding sites in the rat brain. Eur Neuropsychopharmacol 2020; 41:106-117. [PMID: 33153853 PMCID: PMC7731940 DOI: 10.1016/j.euroneuro.2020.10.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 09/02/2020] [Accepted: 10/16/2020] [Indexed: 11/02/2022]
Abstract
Postmortem studies suggest that schizophrenia is associated with abnormal expression of specific GABAA receptor (GABAAR) α subunits, including α5GABAAR. Positron emission tomography (PET) measures of GABAAR availability in schizophrenia, however, have not revealed consistent alterations in vivo. Animal studies using the GABAAR agonist [3H]-muscimol provide evidence that antipsychotic drugs influence GABAAR availability, in a region-specific manner, suggesting a potential confounding effect of these drugs. No such data, however, are available for more recently developed subunit-selective GABAAR radioligands. To address this, we combined a rat model of clinically relevant antipsychotic drug exposure with quantitative receptor autoradiography. Haloperidol (0.5 and 2 mg/kg/day) or drug vehicle were administered continuously to adult male Sprague-Dawley rats via osmotic mini-pumps for 28 days. Quantitative receptor autoradiography was then performed postmortem using the GABAAR subunit-selective radioligand [3H]-Ro15-4513 and the non-subunit selective radioligand [3H]-flumazenil. Chronic haloperidol exposure increased [3H]-Ro15-4513 binding in the CA1 sub-field of the rat dorsal hippocampus (p<0.01; q<0.01; d=+1.3), which was not dose-dependent. [3H]-flumazenil binding also increased in most rat brain regions (p<0.05; main effect of treatment), irrespective of the haloperidol dose. These data confirm previous findings that chronic haloperidol exposure influences the specific binding of non-subtype selective GABAAR radioligands and is the first to demonstrate a potential effect of haloperidol on the binding of a α1/5GABAAR-selective radioligand. Although caution should be exerted when extrapolating results from animals to patients, our data support a view that exposure to antipsychotics may be a confounding factor in PET studies of GABAAR in the context of schizophrenia.
Collapse
Affiliation(s)
- Alba Peris-Yague
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
| | - Amanda Kiemes
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespingy Park, London SE5 8AF, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
| | - Marie-Caroline Cotel
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, United Kingdom
| | - Nisha Singh
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, United Kingdom; MRC Centre for Neurodevelopmental Disorders, King's College London, London, United Kingdom.
| | - Gemma Modinos
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespingy Park, London SE5 8AF, United Kingdom; MRC Centre for Neurodevelopmental Disorders, King's College London, London, United Kingdom.
| |
Collapse
|
31
|
Polsek D, Cash D, Veronese M, Ilic K, Wood TC, Milosevic M, Kalanj-Bognar S, Morrell MJ, Williams SCR, Gajovic S, Leschziner GD, Mitrecic D, Rosenzweig I. The innate immune toll-like-receptor-2 modulates the depressogenic and anorexiolytic neuroinflammatory response in obstructive sleep apnoea. Sci Rep 2020; 10:11475. [PMID: 32651433 PMCID: PMC7351955 DOI: 10.1038/s41598-020-68299-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 06/16/2020] [Indexed: 12/19/2022] Open
Abstract
The increased awareness of obstructive sleep apnoea’s (OSA) links to Alzheimer’s disease and major psychiatric disorders has recently directed an intensified search for their potential shared mechanisms. We hypothesised that neuroinflammation and the microglial TLR2-system may act as a core process at the intersection of their pathophysiology. Moreover, we postulated that inflammatory-response might underlie development of key behavioural and neurostructural changes in OSA. Henceforth, we set out to investigate effects of 3 weeks’ exposure to chronic intermittent hypoxia in mice with or without functional TRL2 (TLR2+/+, C57BL/6-Tyrc-Brd-Tg(Tlr2-luc/gfp)Kri/Gaj;TLR2−/−,C57BL/6-Tlr2tm1Kir). By utilising multimodal imaging in this established model of OSA, a discernible neuroinflammatory response was demonstrated for the first time. The septal nuclei and forebrain were shown as the initial key seed-sites of the inflammatory cascade that led to wider structural changes in the associated neurocircuitry. Finally, the modulatory role for the functional TLR2-system was suggested in aetiology of depressive, anxious and anorexiolytic symptoms in OSA.
Collapse
Affiliation(s)
- Dora Polsek
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK.,University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia
| | - Diana Cash
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK.,BRAIN, Department of Neuroimaging, KCL, London, UK
| | | | - Katarina Ilic
- University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia
| | | | - Milan Milosevic
- School of Public Health, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Svjetlana Kalanj-Bognar
- University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia
| | - Mary J Morrell
- The National Heart and Lung Institute, Imperial College London, London, UK
| | | | - Srecko Gajovic
- University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia
| | - Guy D Leschziner
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK.,Department of Neurology, Guy's and St Thomas' Hospital (GSTT) and Clinical Neurosciences, KCL, London, UK.,Sleep Disorders Centre, GSTT, London, UK
| | - Dinko Mitrecic
- University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia
| | - Ivana Rosenzweig
- Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK. .,Sleep Disorders Centre, GSTT, London, UK.
| |
Collapse
|
32
|
Morgan CA, Mesquita M, Ashioti M, Beech JS, Williams SCR, Irving E, Cash D. Late changes in blood-brain barrier permeability in a rat tMCAO model of stroke detected by gadolinium-enhanced MRI. Neurol Res 2020; 42:844-852. [PMID: 32600164 DOI: 10.1080/01616412.2020.1786637] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
OBJECTIVES After cerebral ischaemia the blood-brain barrier (BBB) may be compromised and this has been observed in both clinical and preclinical studies. The timing of BBB disruption after ischaemia has long been considered to be biphasic, however some groups contest this view. Therefore, the purpose of this study was to characterize the BBB permeability timecourse in a rat model at both acute and chronic time points. METHODS Unilateral transient middle cerebral artery occlusion (tMCAO) was performed in 15 male Sprague Dawley rats. Change in T1-weighted MR signal before and after an injection of gadolinium-based contrast agent was calculated voxelwise to derive a BBB permeability index (BBBPI) at both early (6 h, 12 h, and 24 h) and late (7 and 14 days) time points. RESULTS As expected, BBBPI in the non-lesioned ROI was not significantly different from pre-occlusion baseline at any time point. However, BBBPI in the ipsilateral (lesioned) ROI was statistically different to baseline at day 7 (p < 0.001) and day 14 (p < 0.01) post-tMCAO. There was a small, but not-significant increase in BBBPI in the earlier phase (at 6 hours). DISCUSSION Our results indicate a significant late opening of the BBB. This is important as the majority of previous studies have only characterised an early acute BBB permeability in ischemia. However, the later period of increased permeability may indicate an optimal time for drug delivery across the BBB, when it is especially suited to drugs targeting delayed processes.
Collapse
Affiliation(s)
- Catherine A Morgan
- School of Psychology and Centre for Brain Research, The University of Auckland , Auckland, New Zealand.,Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London , London, UK
| | - Michel Mesquita
- School of Psychology and Centre for Brain Research, The University of Auckland , Auckland, New Zealand
| | - Maria Ashioti
- School of Life Sciences, College of Liberal Arts and Sciences, University of Westminster , London, UK
| | - John S Beech
- School of Psychology and Centre for Brain Research, The University of Auckland , Auckland, New Zealand
| | - Steve C R Williams
- School of Psychology and Centre for Brain Research, The University of Auckland , Auckland, New Zealand
| | - Elaine Irving
- Value Evidence & Outcomes, GlaxoSmithKline R&D Ltd , Stevenage, UK
| | - Diana Cash
- School of Psychology and Centre for Brain Research, The University of Auckland , Auckland, New Zealand
| |
Collapse
|
33
|
Mota F, Sementa T, Taddei C, Moses N, Bordoloi J, Hader S, Eykyn T, Cash D, Turkheimer F, Veronese M, Singh N. Investigating the effects of ebselen, a potential new lithium mimetic, on glutamate transmission. Synapse 2020; 74:e22151. [PMID: 32056277 DOI: 10.1002/syn.22151] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 02/11/2020] [Accepted: 02/11/2020] [Indexed: 11/10/2022]
Abstract
Ebselen, a potential new lithium-like drug, treatment reduced brain glutamate, as measured by PET imaging using the mGluR5 radioligand [18 F]FPEB in rats.
Collapse
Affiliation(s)
- Filipa Mota
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Teresa Sementa
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Carlotta Taddei
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Natasha Moses
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, UK
| | - Jayanta Bordoloi
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Stefan Hader
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Thomas Eykyn
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, UK
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, UK
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, UK
| | - Nisha Singh
- School of Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College, London, UK.,Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, UK
| |
Collapse
|
34
|
White MA, Lin Z, Kim E, Henstridge CM, Pena Altamira E, Hunt CK, Burchill E, Callaghan I, Loreto A, Brown-Wright H, Mead R, Simmons C, Cash D, Coleman MP, Sreedharan J. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol Commun 2019; 7:166. [PMID: 31661035 PMCID: PMC6819591 DOI: 10.1186/s40478-019-0800-9] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 08/30/2019] [Indexed: 02/05/2023] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition that primarily affects the motor system and shares many features with frontotemporal dementia (FTD). Evidence suggests that ALS is a 'dying-back' disease, with peripheral denervation and axonal degeneration occurring before loss of motor neuron cell bodies. Distal to a nerve injury, a similar pattern of axonal degeneration can be seen, which is mediated by an active axon destruction mechanism called Wallerian degeneration. Sterile alpha and TIR motif-containing 1 (Sarm1) is a key gene in the Wallerian pathway and its deletion provides long-term protection against both Wallerian degeneration and Wallerian-like, non-injury induced axonopathy, a retrograde degenerative process that occurs in many neurodegenerative diseases where axonal transport is impaired. Here, we explored whether Sarm1 signalling could be a therapeutic target for ALS by deleting Sarm1 from a mouse model of ALS-FTD, a TDP-43Q331K, YFP-H double transgenic mouse. Sarm1 deletion attenuated motor axon degeneration and neuromuscular junction denervation. Motor neuron cell bodies were also significantly protected. Deletion of Sarm1 also attenuated loss of layer V pyramidal neuronal dendritic spines in the primary motor cortex. Structural MRI identified the entorhinal cortex as the most significantly atrophic region, and histological studies confirmed a greater loss of neurons in the entorhinal cortex than in the motor cortex, suggesting a prominent FTD-like pattern of neurodegeneration in this transgenic mouse model. Despite the reduction in neuronal degeneration, Sarm1 deletion did not attenuate age-related behavioural deficits caused by TDP-43Q331K. However, Sarm1 deletion was associated with a significant increase in the viability of male TDP-43Q331K mice, suggesting a detrimental role of Wallerian-like pathways in the earliest stages of TDP-43Q331K-mediated neurodegeneration. Collectively, these results indicate that anti-SARM1 strategies have therapeutic potential in ALS-FTD.
Collapse
Affiliation(s)
- Matthew A White
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
| | - Ziqiang Lin
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
- West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Eugene Kim
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King's College London, London, UK
| | | | - Emiliano Pena Altamira
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
| | - Camille K Hunt
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
| | - Ella Burchill
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
| | - Isobel Callaghan
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK
| | - Andrea Loreto
- John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Heledd Brown-Wright
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
| | - Richard Mead
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
| | - Camilla Simmons
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King's College London, London, UK
| | - Diana Cash
- BRAIN Centre (Biomarker Research And Imaging for Neuroscience), Department of Neuroimaging, IoPPN, King's College London, London, UK
| | - Michael P Coleman
- John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- Signalling Programme, Babraham Institute, Babraham Research Campus, Cambridge, UK
| | - Jemeen Sreedharan
- Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 9RT, UK.
| |
Collapse
|
35
|
Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, Gee A, Halldin C, Veronese M, Bölte S, Farde L, Sementa T, Cash D, Higgins K, Spain D, Turkheimer F, Mick I, Selvaraj S, Nutt DJ, Lingford-Hughes A, Howes OD, Murphy DG, Borg J. GABA A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Sci Transl Med 2019; 10:10/461/eaam8434. [PMID: 30282698 DOI: 10.1126/scitranslmed.aam8434] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 08/15/2017] [Accepted: 12/15/2017] [Indexed: 01/16/2023]
Abstract
Preliminary studies have suggested that γ-aminobutyric acid type A (GABAA) receptors, and potentially the GABAA α5 subtype, are deficient in autism spectrum disorder (ASD). However, prior studies have been confounded by the effects of medications, and these studies did not compare findings across different species. We measured both total GABAA and GABAA α5 receptor availability in two positron emission tomography imaging studies. We used the tracer [11C]flumazenil in 15 adults with ASD and in 15 control individuals without ASD and the tracer [11C]Ro15-4513 in 12 adults with ASD and in 16 control individuals without ASD. All participants were free of medications. We also performed autoradiography, using the same tracers, in three mouse models of ASD: the Cntnap2 knockout mouse, the Shank3 knockout mouse, and mice carrying a 16p11.2 deletion. We found no differences in GABAA receptor or GABAA α5 subunit availability in any brain region of adults with ASD compared to those without ASD. There were no differences in GABAA receptor or GABAA α5 subunit availability in any of the three mouse models. However, adults with ASD did display altered performance on a GABA-sensitive perceptual task. Our data suggest that GABAA receptor availability may be normal in adults with ASD, although GABA signaling may be functionally impaired.
Collapse
Affiliation(s)
- Jamie Horder
- Department of Forensic and Neurodevelopmental Sciences and Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Max Andersson
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Maria A Mendez
- Department of Forensic and Neurodevelopmental Sciences and Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Nisha Singh
- Department of Neuroimaging, Institute of Psychiatry Psychology, and Neuroscience, King's College London, London, UK.,Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
| | - Ämma Tangen
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Johan Lundberg
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Antony Gee
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
| | - Christer Halldin
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry Psychology, and Neuroscience, King's College London, London, UK
| | - Sven Bölte
- Center of Neurodevelopmental Disorders at Karolinska Institutet (KIND), Pediatric Neuropsychiatry Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.,Child and Adolescent Psychiatry, Center for Psychiatry Research, Stockholm County Council, Stockholm, Sweden
| | - Lars Farde
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.,Personalised Healthcare and Biomarkers, AstraZeneca, PET Science Centre, Karolinska Institutet, Stockholm, Sweden
| | - Teresa Sementa
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry Psychology, and Neuroscience, King's College London, London, UK
| | - Karen Higgins
- Department of Neuroimaging, Institute of Psychiatry Psychology, and Neuroscience, King's College London, London, UK
| | - Debbie Spain
- Department of Forensic and Neurodevelopmental Sciences and Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Federico Turkheimer
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK
| | - Inge Mick
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK
| | - Sudhakar Selvaraj
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK
| | - David J Nutt
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK
| | - Anne Lingford-Hughes
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK
| | - Oliver D Howes
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Declan G Murphy
- Department of Forensic and Neurodevelopmental Sciences and Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
| | - Jacqueline Borg
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.,Center of Neurodevelopmental Disorders at Karolinska Institutet (KIND), Pediatric Neuropsychiatry Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
36
|
Mancuso R, Fryatt G, Cleal M, Obst J, Pipi E, Monzón-Sandoval J, Ribe E, Winchester L, Webber C, Nevado A, Jacobs T, Austin N, Theunis C, Grauwen K, Daniela Ruiz E, Mudher A, Vicente-Rodriguez M, Parker CA, Simmons C, Cash D, Richardson J. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 2019; 142:3243-3264. [PMID: 31504240 PMCID: PMC6794948 DOI: 10.1093/brain/awz241] [Citation(s) in RCA: 130] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 06/11/2019] [Accepted: 06/14/2019] [Indexed: 11/12/2022] Open
Abstract
Neuroinflammation and microglial activation are significant processes in Alzheimer's disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer's disease, and experimental data have demonstrated microglial proliferation as a significant component of the neuropathology. In this study, we tested the efficacy of the selective CSF1R inhibitor JNJ-40346527 (JNJ-527) in the P301S mouse tauopathy model. We first demonstrated the anti-proliferative effects of JNJ-527 on microglia in the ME7 prion model, and its impact on the inflammatory profile, and provided potential CNS biomarkers for clinical investigation with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autoradiography and CSF proteomics. Then, we showed for the first time that blockade of microglial proliferation and modification of microglial phenotype leads to an attenuation of tau-induced neurodegeneration and results in functional improvement in P301S mice. Overall, this work strongly supports the potential for inhibition of CSF1R as a target for the treatment of Alzheimer's disease and other tau-mediated neurodegenerative diseases.
Collapse
Affiliation(s)
- Renzo Mancuso
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Gemma Fryatt
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Madeleine Cleal
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Juliane Obst
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Elena Pipi
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Jimena Monzón-Sandoval
- Department of Physiology Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, UK
- UK Dementia Research Institute, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK
| | - Elena Ribe
- Department of Physiology Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, UK
| | - Laura Winchester
- Department of Physiology Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, UK
| | - Caleb Webber
- Department of Physiology Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, UK
- UK Dementia Research Institute, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK
| | - Alejo Nevado
- Department of Physiology Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, UK
| | - Tom Jacobs
- Janssen Research and Development, Turnhoutseweg 30, box 270, 2340 Beerse 1, Belgium
| | - Nigel Austin
- Janssen Research and Development, Turnhoutseweg 30, box 270, 2340 Beerse 1, Belgium
| | - Clara Theunis
- Janssen Neuroscience Research and Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium
| | - Karolien Grauwen
- Janssen Neuroscience Research and Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium
| | - Eva Daniela Ruiz
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Amrit Mudher
- Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Marta Vicente-Rodriguez
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Christine A Parker
- Experimental Medicine Imaging, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Jill Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK
| |
Collapse
|
37
|
So PW, Ekonomou A, Galley K, Brody L, Sahuri-Arisoylu M, Rattray I, Cash D, Bell JD. Intraperitoneal delivery of acetate-encapsulated liposomal nanoparticles for neuroprotection of the penumbra in a rat model of ischemic stroke. Int J Nanomedicine 2019; 14:1979-1991. [PMID: 30936698 PMCID: PMC6430000 DOI: 10.2147/ijn.s193965] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background Ischemic stroke is a devastating condition, with metabolic derangement and persistent inflammation enhancing the initial insult of ischaemia. Recombinant tissue plasminogen remains the only effective treatment but limited as therapy must commence soon after the onset of symptoms. Purpose We investigated whether acetate, which modulates many pathways including inflammation, may attenuate brain injury in stroke. As acetate has a short blood half-life and high amounts irritate the gastrointestinal tract, acetate was administered encapsulated in a liposomal nanoparticle (liposomal-encapsulated acetate, LITA). Methods Transient ischemia was induced by 90 mins middle-cerebral artery occlusion (MCAO) in Sprague-Dawley rats, and LITA or control liposomes given intraperitoneally at occlusion and daily for up to two weeks post-MCAO. Magnetic resonance imaging (MRI) was used to estimate lesion volume at 24 h, 1 and 2 weeks post-MCAO and anterior lateral ventricular volume (ALVv) at 2 weeks post-MCAO. Locomotive behaviour was tested prior to the final MRI scan. After the final scan, brains were collected, and immunohistochemistry was performed. Results Lesion volumes were decreased by ~80% from 24 h to one-week post-MCAO, in both control and LITA groups (P⩽0.05). However, the lesion was increased by ~50% over the subsequent 1 to 2 weeks after MCAO in the control group (from 24.1±10.0 to 58.7±28.6 mm3; P⩽0.05) but remained unchanged in the LITA group. ALVv were also attenuated by LITA treatment at 2 weeks post-MCAO (177.2±11.9% and 135.3±10.9% of contralateral ALVv for control and LITA groups, respectively; P⩽0.05). LITA-treated animals also appeared to have improved motor activity, moving with greater average velocity than control animals. Microglial immunoreactivity was ~40% lower in the LITA group compared to the control group (P⩽0.05), but LITA did not modulate neurogenesis, apoptosis, histone acetylation and lipid peroxidation. Conclusion LITA appears to attenuate the harmful chronic neuroinflammation observed during brain remodeling after a focal ischemic insult.
Collapse
Affiliation(s)
- Po-Wah So
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Neuroimaging, London, UK,
| | - Antigoni Ekonomou
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Neuroimaging, London, UK,
| | - Kim Galley
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Neuroimaging, London, UK,
| | - Leigh Brody
- University of Westminster, Research Centre for Optimal Health, London, UK
| | | | - Ivan Rattray
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, London, UK
| | - Diana Cash
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Neuroimaging, London, UK,
| | - Jimmy D Bell
- University of Westminster, Research Centre for Optimal Health, London, UK
| |
Collapse
|
38
|
Duricki DA, Drndarski S, Bernanos M, Wood T, Bosch K, Chen Q, Shine HD, Simmons C, Williams SCR, McMahon SB, Begley DJ, Cash D, Moon LDF. Stroke Recovery in Rats after 24-Hour-Delayed Intramuscular Neurotrophin-3 Infusion. Ann Neurol 2018; 85:32-46. [PMID: 30525223 PMCID: PMC6492080 DOI: 10.1002/ana.25386] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 11/28/2018] [Accepted: 11/28/2018] [Indexed: 12/30/2022]
Abstract
Objective Neurotrophin‐3 (NT3) plays a key role in the development and function of locomotor circuits including descending serotonergic and corticospinal tract axons and afferents from muscle and skin. We have previously shown that gene therapy delivery of human NT3 into affected forelimb muscles improves sensorimotor recovery after stroke in adult and elderly rats. Here, to move toward the clinic, we tested the hypothesis that intramuscular infusion of NT3 protein could improve sensorimotor recovery after stroke. Methods Rats received unilateral ischemic stroke in sensorimotor cortex. To simulate a clinically feasible time to treatment, 24 hours later rats were randomized to receive NT3 or vehicle by infusion into affected triceps brachii for 4 weeks using implanted catheters and minipumps. Results Radiolabeled NT3 crossed from the bloodstream into the brain and spinal cord in rodents with or without strokes. NT3 increased the accuracy of forelimb placement during walking on a horizontal ladder and increased use of the affected arm for lateral support during rearing. NT3 also reversed sensory impairment of the affected wrist. Functional magnetic resonance imaging during stimulation of the affected wrist showed spontaneous recovery of peri‐infarct blood oxygenation level–dependent signal that NT3 did not further enhance. Rather, NT3 induced neuroplasticity of the spared corticospinal and serotonergic pathways. Interpretation Our results show that delayed, peripheral infusion of NT3 can improve sensorimotor function after ischemic stroke. Phase I and II clinical trials of NT3 (for constipation and neuropathy) have shown that peripheral high doses are safe and well tolerated, which paves the way for NT3 as a therapy for stroke. ANN NEUROL 2019;85:32–46.
Collapse
Affiliation(s)
- Denise A Duricki
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom.,Centre for Integrative Biology, King's College London, London, United Kingdom
| | - Svetlana Drndarski
- Blood-Brain Barrier Group, Institute of Pharmaceutical Science, King's College London, London, United Kingdom
| | - Michel Bernanos
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Tobias Wood
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Karen Bosch
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - Qin Chen
- Center for Cell and Gene Therapy, Department of Neuroscience, Baylor College of Medicine, Houston, TX
| | - H David Shine
- Center for Cell and Gene Therapy, Department of Neuroscience, Baylor College of Medicine, Houston, TX
| | - Camilla Simmons
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | | | - Stephen B McMahon
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - David J Begley
- Blood-Brain Barrier Group, Institute of Pharmaceutical Science, King's College London, London, United Kingdom
| | - Diana Cash
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Lawrence D F Moon
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom.,Centre for Integrative Biology, King's College London, London, United Kingdom
| |
Collapse
|
39
|
Singh N, Veronese M, O'Doherty J, Sementa T, Bongarzone S, Cash D, Simmons C, Arcolin M, Marsden PK, Gee A, Turkheimer FE. Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging. Nucl Med Biol 2018; 66:32-39. [PMID: 30208358 PMCID: PMC6288068 DOI: 10.1016/j.nucmedbio.2018.08.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 08/18/2018] [Accepted: 08/23/2018] [Indexed: 01/17/2023]
Abstract
Introduction The development of clinically useful tracers for PET imaging is enormously challenging and expensive. The intranasal (IN) route of administration is purported to be a viable route for delivering drugs to the brain but has, as yet, not been investigated for the delivery of PET tracers. If the intranasal (IN) pathway presents a viable option, it extends the PET imaging field by increasing the number of tracers available for human use. Here we report the results of a rodent study testing the feasibility of the IN route to administer radiotracers for brain PET imaging. Methods We used two different, well characterised, brain penetrant radiotracers, [18F]fluorodeoxyglucose ([18F]FDG) and [18F]fallypride, and aimed to evaluate the pharmacokinetics after administration of the tracers via the intranasal route, and contrast this to intravenous administration. Image acquisition was carried out after tracer administration and arterial blood samples were collected at different time intervals, centrifuged to extract plasma and gamma counted. We hypothesised that [brain region]:[plasma] ratios would be higher via the intranasal route as there are two inputs, one directly from the nose to the brain, and another from the peripheral circulation. To assess the feasibility of using this approach clinically, we used these data to estimate radiation dosimetry in humans. Results Contrary to our hypothesis, in case of both radiotracers, we did not see a higher ratio in the expected brain regions, except in the olfactory bulb, that is closest to the nose. It appears that the radiotracers move into the olfactory bulb region, but then do not progress further into other brain regions. Moreover, as the nasal cavity has a small surface area, the extrapolated dosimetry estimations for intranasal human imaging showed an unacceptably high level (15 mSv/MBq) of cumulative skin radiation exposure. Conclusions Therefore, although an attractive route for brain permeation, we conclude that the intranasal route would present difficulties due to non-specific signal and radiation dosimetry considerations for brain PET imaging.
Collapse
Affiliation(s)
- Nisha Singh
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom; School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom
| | - Jim O'Doherty
- PET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom; Department of Molecular Imaging, Sidra Medicine, Doha, Qatar
| | - Teresa Sementa
- School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom
| | - Salvatore Bongarzone
- School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom
| | - Marco Arcolin
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom
| | - Paul K Marsden
- School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom; PET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom
| | - Antony Gee
- School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom; PET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom
| | - Federico E Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom
| |
Collapse
|
40
|
Walker SE, Wood TC, Cash D, Mesquita M, Williams SCR, Sandi C. Alterations in brain microstructure in rats that develop abnormal aggression following peripubertal stress. Eur J Neurosci 2018; 48:1818-1832. [PMID: 29961949 DOI: 10.1111/ejn.14061] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 06/15/2018] [Accepted: 06/26/2018] [Indexed: 01/01/2023]
Abstract
Exposure to early adversity is implicated in the development of aggressive behaviour later in life in some but not all individuals. The reasons for the variability in response to such experiences are not clear but may relate to pre-existing individual differences that influence their downstream effects. Applying structural magnetic resonance imaging (MRI) to a rat model of abnormal aggression induced by peripubertal stress, we examined whether individual differences in the development of an aggressive phenotype following stress exposure were underpinned by variation in the structure of aggression-associated, corticolimbic brain regions. We also assessed whether responsiveness of the hypothalamic-pituitary-adrenal axis to stress was associated with neurobehavioural outcome following adversity. A subset of the rats exposed to peripubertal stress developed an aggressive phenotype, while the remaining rats were affected in other behavioural domains, such as increased anxiety-like behaviours and reduced sociability. Peripubertal stress led to changes in tissue microstructure within prefrontal cortex, amygdala and hippocampal formation only in those individuals displaying an aggressive phenotype. Attenuated glucocorticoid response to stress during juvenility predicted the subsequent development of an aggressive phenotype in peripubertal stress-exposed rats. Our study establishes a link between peripubertal stress exposure in rats and structural deviations in brain regions linked to abnormal aggression and points towards low glucocorticoid responsiveness to stress as a potential underlying mechanism. We additionally highlight the importance of considering individual differences in behavioural response to stress when determining neurobiological correlates.
Collapse
Affiliation(s)
- Sophie E Walker
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Tobias C Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Michel Mesquita
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Steven C R Williams
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Carmen Sandi
- Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| |
Collapse
|
41
|
Polsek D, Gildeh N, Cash D, Winsky-Sommerer R, Williams SCR, Turkheimer F, Leschziner GD, Morrell MJ, Rosenzweig I. Obstructive sleep apnoea and Alzheimer's disease: In search of shared pathomechanisms. Neurosci Biobehav Rev 2018; 86:142-149. [PMID: 29223769 PMCID: PMC6562163 DOI: 10.1016/j.neubiorev.2017.12.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 10/29/2017] [Accepted: 12/04/2017] [Indexed: 12/12/2022]
Abstract
Alzheimer's disease (AD) is a significant public health concern. The incidence continues to rise, and it is set to be over one million in the UK by 2025. The processes involved in the pathogenesis of AD have been shown to overlap with those found in cognitive decline in patients with Obstructive Sleep Apnoea (OSA). Currently, the standard treatment for OSA is Continuous Positive Airway Pressure. Adherence to treatment can, however, be an issue, especially in patients with dementia. Also, not all patients respond adequately, necessitating the use of additional treatments. Based on the body of data, we here suggest that excessive and prolonged neuronal activity might contribute to genesis and acceleration of both AD and OSA in the absence of appropriately structured sleep. Further, we argue that external factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain, and further promote disease progression. If this hypothesis is proven in future studies, it could have far-reaching clinical translational implications, as well as implications for future treatment strategies in OSA.
Collapse
Affiliation(s)
- D Polsek
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Croatian Institute for Brain Research, Medical School, University of Zagreb, Croatia
| | - N Gildeh
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK
| | - D Cash
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Department of Neuroimaging, IoPPN, King's College London, UK
| | - R Winsky-Sommerer
- Surrey Sleep Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - S C R Williams
- Department of Neuroimaging, IoPPN, King's College London, UK
| | - F Turkheimer
- Department of Neuroimaging, IoPPN, King's College London, UK
| | - G D Leschziner
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK; Department of Neurology, Guy's and St Thomas' Hospital, London, UK
| | - M J Morrell
- Academic Unit of Sleep and Breathing, National Heart and Lung Institute, Imperial College London, UK and NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, UK
| | - I Rosenzweig
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK.
| |
Collapse
|
42
|
Polsek D, Gildeh N, Cash D, Winsky-Sommerer R, Williams SCR, Turkheimer F, Leschziner GD, Morrell MJ, Rosenzweig I. Obstructive sleep apnoea and Alzheimer's disease: In search of shared pathomechanisms. Neurosci Biobehav Rev 2017. [PMID: 29223769 DOI: 10.1016/j.neubiorev.2017.12.004.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
Abstract
Alzheimer's disease (AD) is a significant public health concern. The incidence continues to rise, and it is set to be over one million in the UK by 2025. The processes involved in the pathogenesis of AD have been shown to overlap with those found in cognitive decline in patients with Obstructive Sleep Apnoea (OSA). Currently, the standard treatment for OSA is Continuous Positive Airway Pressure. Adherence to treatment can, however, be an issue, especially in patients with dementia. Also, not all patients respond adequately, necessitating the use of additional treatments. Based on the body of data, we here suggest that excessive and prolonged neuronal activity might contribute to genesis and acceleration of both AD and OSA in the absence of appropriately structured sleep. Further, we argue that external factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain, and further promote disease progression. If this hypothesis is proven in future studies, it could have far-reaching clinical translational implications, as well as implications for future treatment strategies in OSA.
Collapse
Affiliation(s)
- D Polsek
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Croatian Institute for Brain Research, Medical School, University of Zagreb, Croatia
| | - N Gildeh
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK
| | - D Cash
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Department of Neuroimaging, IoPPN, King's College London, UK
| | - R Winsky-Sommerer
- Surrey Sleep Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
| | - S C R Williams
- Department of Neuroimaging, IoPPN, King's College London, UK
| | - F Turkheimer
- Department of Neuroimaging, IoPPN, King's College London, UK
| | - G D Leschziner
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK; Department of Neurology, Guy's and St Thomas' Hospital, London, UK
| | - M J Morrell
- Academic Unit of Sleep and Breathing, National Heart and Lung Institute, Imperial College London, UK and NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, UK
| | - I Rosenzweig
- Sleep and Brain Plasticity Centre, CNS, IoPPN, King's College London, UK; Sleep Disorders Centre, Guy's and St Thomas' Hospital, London, UK.
| |
Collapse
|
43
|
Westphal R, Simmons C, Mesquita MB, Wood TC, Williams SCR, Vernon AC, Cash D. Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease. PLoS One 2017; 12:e0172394. [PMID: 28249008 PMCID: PMC5382982 DOI: 10.1371/journal.pone.0172394] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 02/03/2017] [Indexed: 01/21/2023] Open
Abstract
Resting-state functional MRI (rsfMRI) is an imaging technology that has recently gained attention for its ability to detect disruptions in functional brain networks in humans, including in patients with Parkinson's disease (PD), revealing early and widespread brain network abnormalities. This methodology is now readily applicable to experimental animals offering new possibilities for cross-species translational imaging. In this context, we herein describe the application of rsfMRI to the unilaterally-lesioned 6-hydroxydopamine (6-OHDA) rat, a robust experimental model of the dopamine depletion implicated in PD. Using graph theory to analyse the rsfMRI data, we were able to provide meaningful and translatable measures of integrity, influence and segregation of the underlying functional brain architecture. Specifically, we confirm that rats share a similar functional brain network topology as observed in humans, characterised by small-worldness and modularity. Interestingly, we observed significantly reduced functional connectivity in the 6-OHDA rats, primarily in the ipsilateral (lesioned) hemisphere as evidenced by significantly lower node degree, local efficiency and clustering coefficient in the motor, orbital and sensorimotor cortices. In contrast, we found significantly, and bilaterally, increased thalamic functional connectivity in the lesioned rats. The unilateral deficits in the cortex are consistent with the unilateral nature of this model and further support the validity of the rsfMRI technique in rodents. We thereby provide a methodological framework for the investigation of brain networks in other rodent experimental models of PD, as well as of animal models in general, for cross-comparison with human data.
Collapse
Affiliation(s)
- Robert Westphal
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Camilla Simmons
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Michel B. Mesquita
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Tobias C. Wood
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Steve C. R. Williams
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Anthony C. Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| |
Collapse
|
44
|
Tomimatsu Y, Cash D, Suzuki M, Suzuki K, Bernanos M, Simmons C, Williams SC, Kimura H. TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge. Neuroscience 2016; 339:180-190. [DOI: 10.1016/j.neuroscience.2016.10.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 09/30/2016] [Accepted: 10/02/2016] [Indexed: 02/06/2023]
|
45
|
Wood TC, Simmons C, Hurley SA, Vernon AC, Torres J, Dell’Acqua F, Williams SC, Cash D. Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. PeerJ 2016; 4:e2632. [PMID: 27833805 PMCID: PMC5101606 DOI: 10.7717/peerj.2632] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Accepted: 09/29/2016] [Indexed: 11/20/2022] Open
Abstract
Myelin is a critical component of the nervous system and a major contributor to contrast in Magnetic Resonance (MR) images. However, the precise contribution of myelination to multiple MR modalities is still under debate. The cuprizone mouse is a well-established model of demyelination that has been used in several MR studies, but these have often imaged only a single slice and analysed a small region of interest in the corpus callosum. We imaged and analyzed the whole brain of the cuprizone mouse ex-vivo using high-resolution quantitative MR methods (multi-component relaxometry, Diffusion Tensor Imaging (DTI) and morphometry) and found changes in multiple regions, including the corpus callosum, cerebellum, thalamus and hippocampus. The presence of inflammation, confirmed with histology, presents difficulties in isolating the sensitivity and specificity of these MR methods to demyelination using this model.
Collapse
Affiliation(s)
- Tobias C. Wood
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| | - Camilla Simmons
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| | - Samuel A. Hurley
- FMRIB Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, United Kingdom
- Synaptive Medical, Toronto, ON, Canada
| | - Anthony C. Vernon
- Cells and Behaviour Unit, Department of Basic and Clinical Neuroscience, IOPPN, King’s College London, London, United Kingdom
| | - Joel Torres
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| | - Flavio Dell’Acqua
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
- NatBrainLab, Department of Basic and Clinical Neuroscience, IOPPN, King’s College London, London, United Kingdom
| | - Steve C.R. Williams
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| | - Diana Cash
- Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| |
Collapse
|
46
|
Wayman C, Duricki DA, Roy LA, Haenzi B, Tsai SY, Kartje G, Beech JS, Cash D, Moon L. Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability. J Vis Exp 2016:53106. [PMID: 26967269 PMCID: PMC4828187 DOI: 10.3791/53106] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Stroke typically occurs in elderly people with a range of comorbidities including carotid (or other arterial) atherosclerosis, high blood pressure, obesity and diabetes. Accordingly, when evaluating therapies for stroke in animals, it is important to select a model with excellent face validity. Ischemic stroke accounts for 80% of all strokes, and the majority of these occur in the territory of the middle cerebral artery (MCA), often inducing infarcts that affect the sensorimotor cortex, causing persistent plegia or paresis on the contralateral side of the body. We demonstrate in this video a method for producing ischemic stroke in elderly rats, which causes sustained sensorimotor disability and substantial cortical infarcts. Specifically, we induce permanent distal middle cerebral artery occlusion (MCAO) in elderly female rats by using diathermy forceps to occlude a short segment of this artery. The carotid artery on the ipsilateral side to the lesion was then permanently occluded and the contralateral carotid artery was transiently occluded for 60 min. We measure the infarct size using structural T2-weighted magnetic resonance imaging (MRI) at 24 hr and 8 weeks after stroke. In this study, the mean infarct volume was 4.5% ± 2.0% (standard deviation) of the ipsilateral hemisphere at 24 hr (corrected for brain swelling using Gerriet's equation, n = 5). This model is feasible and clinically relevant as it permits the induction of sustained sensorimotor deficits, which is important for the elucidation of pathophysiological mechanisms and novel treatments.
Collapse
Affiliation(s)
- Christina Wayman
- Wolfson Centre for Age-Related Diseases, King's College London, University of London; Department of Neuroimaging, James Black Centre, Institute of Psychiatry, King's College London, University of London
| | - Denise A Duricki
- Wolfson Centre for Age-Related Diseases, King's College London, University of London; Department of Neuroimaging, James Black Centre, Institute of Psychiatry, King's College London, University of London
| | - Lisa A Roy
- Institute of Neuroscience and Psychology, Wellcome Surgical Institute, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow
| | - Barbara Haenzi
- Wolfson Centre for Age-Related Diseases, King's College London, University of London
| | | | - Gwendolyn Kartje
- Research Service, Edward Hines Jr. VA Hospital; Neurology Service, Edward Hines Jr. VA Hospital; Department of Molecular Pharmacology and Therapeutics, Neuroscience Research Institute, Loyola University Chicago
| | - John S Beech
- Department of Oncology, The Gray Institute for Radiation, Oncology and Biology, University of Oxford
| | - Diana Cash
- Department of Neuroimaging, James Black Centre, Institute of Psychiatry, King's College London, University of London
| | - Lawrence Moon
- Wolfson Centre for Age-Related Diseases, King's College London, University of London;
| |
Collapse
|
47
|
Cash D, Easton AC, Mesquita M, Beech J, Williams S, Lloyd A, Irving E, Cramer SC. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci 2016; 2:28-33. [PMID: 28018988 PMCID: PMC5179224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Myelin-associated glycoprotein (MAG) is an inhibitor of axon growth. MAG levels increase after stroke. GSK249320 is a monoclonal antibody that neutralizes MAG-mediated inhibition and so may promote axon outgrowth and improve post-stroke outcomes. The current study tested the hypothesis that GSK249320 initiated 24 hours or 7 days after experimental stroke improves behavioural outcomes. Rats with right middle cerebral artery occlusion for 90 minutes were randomized to receive 6 weeks of intravenous (a) GSK249320 starting 24 hours post-stroke, (b) GSK249320 starting 7 days post-stroke, or (c) vehicle. Behavioral testing was performed over 7 weeks. Serial MRI demonstrated no differences in infarct volume across groups. Animals treated with GSK249320 24 hours post-stroke showed larger increases in Neuroscore (time X group, p = 0.0008) and staircase test (main effect of group, p = 0.0214) as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit. No significant results were found for the sticky tape or cylinder tests. A separate set of animals with experimental stroke received a single intravenous dose of GSK249320 or vehicle at 1 hour, 24 hours, 48 hours or 1 week post-stroke, and immunohistochemistry methods were used to measure GSK249320 distribution; GSK249320 was found in the ipsilesional hemisphere only, the extent of which increased with later times of injection. These data suggest that intravenous GSK249320 penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke and so support the translational potential of this monoclonal antibody as a restorative therapy for patients with stroke.
Collapse
Affiliation(s)
- Diana Cash
- King’s College London, Institute of Psychiatry, UK
| | | | | | - John Beech
- King’s College London, Institute of Psychiatry, UK
| | | | | | - Elaine Irving
- GlaxoSmithKline, Research Development, PCPS QSci, UK
| | - Steven C. Cramer
- Department Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation, University of California, Irvine, CA, USA,Correspondence to: Steven C. Cramer, MD, Department Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation, University of California, Irvine 843 Health Sciences Road Hewitt Hall room 1331 Irvine, CA 92697, USA, Tel: (949) 824-9853, Fax: (949) 824-5488,
| |
Collapse
|
48
|
Duricki DA, Hutson TH, Kathe C, Soleman S, Gonzalez-Carter D, Petruska JC, Shine HD, Chen Q, Wood TC, Bernanos M, Cash D, Williams SCR, Gage FH, Moon LDF. Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke. Brain 2015; 139:259-75. [PMID: 26614754 PMCID: PMC4785394 DOI: 10.1093/brain/awv341] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 09/29/2015] [Indexed: 12/11/2022] Open
Abstract
There is an urgent need for a therapy that reverses disability after stroke when initiated in a time frame suitable for the majority of new victims. We show here that intramuscular delivery of neurotrophin-3 (NT3, encoded by NTF3) can induce sensorimotor recovery when treatment is initiated 24 h after stroke. Specifically, in two randomized, blinded preclinical trials, we show improved sensory and locomotor function in adult (6 months) and elderly (18 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinically approved serotype of adeno-associated viral vector (AAV1). Importantly, AAV1-hNT3 was given in a clinically-feasible timeframe using a straightforward, targeted route (injections into disabled forelimb muscles). Magnetic resonance imaging and histology showed that recovery was not due to neuroprotection, as expected given the delayed treatment. Rather, treatment caused corticospinal axons from the less affected hemisphere to sprout in the spinal cord. This treatment is the first gene therapy that reverses disability after stroke when administered intramuscularly in an elderly body. Importantly, phase I and II clinical trials by others show that repeated, peripherally administered high doses of recombinant NT3 are safe and well tolerated in humans with other conditions. This paves the way for NT3 as a therapy for stroke.
Collapse
Affiliation(s)
- Denise A Duricki
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
| | - Thomas H Hutson
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
| | - Claudia Kathe
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK
| | - Sara Soleman
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 4 John Van Geest Centre for Brain Repair University of Cambridge, The E.D. Adrian Building, Forvie Site, Robinson Way Cambridge, CB2 0PY, UK
| | - Daniel Gonzalez-Carter
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
| | - Jeffrey C Petruska
- 5 Department of Anatomical Sciences and Neurobiology, University of Louisville; Kentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, Louisville, Kentucky, USA
| | - H David Shine
- 6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
| | - Qin Chen
- 6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
| | - Tobias C Wood
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Michel Bernanos
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Diana Cash
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Steven C R Williams
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Fred H Gage
- 8 The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - Lawrence D F Moon
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
| |
Collapse
|
49
|
Alfieri A, Srivastava S, Siow RCM, Cash D, Modo M, Duchen MR, Fraser PA, Williams SCR, Mann GE. Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic Biol Med 2013; 65:1012-1022. [PMID: 24017972 DOI: 10.1016/j.freeradbiomed.2013.08.190] [Citation(s) in RCA: 165] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 08/23/2013] [Accepted: 08/29/2013] [Indexed: 12/30/2022]
Abstract
Disruption of the blood-brain barrier (BBB) and cerebral edema are the major pathogenic mechanisms leading to neurological dysfunction and death after ischemic stroke. The brain protects itself against infarction via activation of endogenous antioxidant defense mechanisms, and we here report the first evidence that sulforaphane-mediated preactivation of nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream target heme oxygenase-1 (HO-1) in the cerebral vasculature protects the brain against stroke. To induce ischemic stroke, Sprague-Dawley rats were subjected to 70 min middle cerebral artery occlusion (MCAo) followed by 4, 24, or 72 h reperfusion. Nrf2 and HO-1 protein expression was upregulated in cerebral microvessels of peri-infarct regions after 4-72 h, with HO-1 preferentially associated with perivascular astrocytes rather than the cerebrovascular endothelium. In naïve rats, treatment with sulforaphane increased Nrf2 expression in cerebral microvessels after 24h. Upregulation of Nrf2 by sulforaphane treatment prior to transient MCAo (1h) was associated with increased HO-1 expression in perivascular astrocytes in peri-infarct regions and cerebral endothelium in the infarct core. BBB disruption, lesion progression, as analyzed by MRI, and neurological deficits were reduced by sulforaphane pretreatment. As sulforaphane pretreatment led to a moderate increase in peroxynitrite generation, we suggest that hormetic preconditioning underlies sulforaphane-mediated protection against stroke. In conclusion, we propose that pharmacological or dietary interventions aimed to precondition the brain via activation of the Nrf2 defense pathway in the cerebral microvasculature provide a novel therapeutic approach for preventing BBB breakdown and neurological dysfunction in stroke.
Collapse
Affiliation(s)
- Alessio Alfieri
- Cardiovascular Division, British Heart Foundation Centre of Research Excellence, School of Medicine, King's College London, London SE1 9NH, UK
| | - Salil Srivastava
- Cardiovascular Division, British Heart Foundation Centre of Research Excellence, School of Medicine, King's College London, London SE1 9NH, UK
| | - Richard C M Siow
- Cardiovascular Division, British Heart Foundation Centre of Research Excellence, School of Medicine, King's College London, London SE1 9NH, UK
| | - Diana Cash
- Centre for Neuroimaging Sciences, Institute of Psychiatry, King's College London, London SE5 8AF, UK
| | - Michel Modo
- Centre for the Cellular Basis of Behaviour, Institute of Psychiatry, King's College London, London SE5 9NU, UK
| | - Michael R Duchen
- Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK
| | - Paul A Fraser
- Cardiovascular Division, British Heart Foundation Centre of Research Excellence, School of Medicine, King's College London, London SE1 9NH, UK
| | - Steven C R Williams
- Centre for Neuroimaging Sciences, Institute of Psychiatry, King's College London, London SE5 8AF, UK
| | - Giovanni E Mann
- Cardiovascular Division, British Heart Foundation Centre of Research Excellence, School of Medicine, King's College London, London SE1 9NH, UK.
| |
Collapse
|
50
|
Guidine PAM, Cash D, Drumond LE, de Souza e Rezende GH, Massensini AR, Williams SCR, Moraes-Santos T, Moraes MFD, Mesquita MBS. Brainstem Structures Are Primarily Affected in an Experimental Model of Severe Scorpion Envenomation. Toxicol Sci 2013; 137:147-57. [DOI: 10.1093/toxsci/kft231] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|